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In venous thrombosis, blood clot formation occurs at an inappropriate site in 
one of the veins, causing obstruction. This usually causes swelling, redness 
and pain at the affected site. Most often the deep veins of the legs are involved, 
but it may also occur in other sites, such as the upper extremity, cerebral sinus, 
liver or retina. Sometimes, parts of a blood clot dislodge and travel through the 
bloodstream. These so-called emboli usually end up in the lungs, where they 
reduce the blood flow, causing a potentially fatal condition called pulmonary 
embolism. 
Venous thrombosis occurs at an incidence rate of approximately 1-2 per 1000 
persons per year1,2,3, with an estimated mortality of approximately 5% in patients 
with deep vein thrombosis of the leg and even 10% in those with pulmonary 
embolism2. A serious complication is the disabling post-thrombotic syndrome, 
occurring in up to 50% of patients with deep vein thrombosis of the leg4. 
Treatment consists of anticoagulant therapy, which is highly effective, but has 
the serious side-effect of bleeding. The annual risk of any bleeding in patients 
using oral anticoagulants is approximately 15% and that of a major hemorrhage 
(intracranial or life-threatening bleeding at other sites) approximately 3%5. 
Venous thrombosis is a multicausal disease, in which genes and environment 
interact6. The strongest risk factor for venous thrombosis is older age, since the 
risk increases exponentially with age2. The most prevalent genetic risk factors 
for venous thrombosis are factor V Leiden mutation7 and prothrombin G20210A 
mutation8, each present in several percent of the population. Environmental 
factors that increase the risk of venous thrombosis include oral contraceptive 
use, hormone replacement therapy, pregnancy, recent delivery, recent surgery, 
major trauma, plaster cast, immobilization and malignant diseases6-9. In the past 
decades, long distance travel, especially by air, has been identified as a risk 
factor for venous thrombosis as well.
The first cases of travel-related venous thrombosis were reported by Jacques 
Louvell in 195110. Since then, many case reports and case-series on venous 
thrombosis associated with long distance travel have been published. After a 
young woman died of pulmonary embolism at Heathrow airport, after a flight 
from Australia to the United Kingdom, the UK government and the European 
Union decided to fund a large international research program on the association 
between air travel and venous thrombosis. This research program was called 
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the WRIGHT project (World Health Organisation Research Into Global Hazards 
of Travel). This project was carried out, under auspices of the World Health 
Organisation, by researchers from the Netherlands (at the department of Clinical 
Epidemiology at the Leiden University Medical Center and the department of 
Vascular Medicine at the Academic Medical Center in Amsterdam) and the 
United Kingdom (at the department for Cardiovascular Sciences at the University 
of Leicester). Several studies were conducted at the same time, to study both 
epidemiologic and pathophysiological aspects of the association between 
venous thrombosis and air travel.  
Thesis outline
This thesis focuses on epidemiological aspects of the association between long 
distance travel and venous thrombosis. 
Chapter 2 summarizes all literature available on the association between venous 
thrombosis and travel so far. Both epidemiological studies and studies on the 
possible mechanisms responsible for the increased risk of venous thrombosis 
after travel are discussed.
In Chapter 3, a study on the use of prophylactic measures to prevent travel-
related thrombosis amongst visitors of three international conferences is 
reported. 
In Chapter 4, we present an estimate of the absolute risk of developing venous 
thrombosis shortly after air travel. Furthermore, the effect of exposure to several 
flights at the same time, duration of flights and time after a long haul flight was 
studied.
In Chapter 5, a study on the effect of elevated coagulation factors and 
combinations with other known risk factors for venous thrombosis (Factor V 
Leiden mutation, prothrombin 20210A mutation, increased body mass index 
and oral contraceptive use) on the risk of venous thrombosis within travellers is 
presented. 
In Chapter 6, we present a study on the effect of transient risk factors for venous 
thrombosis (recent surgery, malignant diseases, plaster cast, oral contraceptive 
use, hormone replacement therapy, pregnancy or recent delivery) on the risk of 
travel-related venous thrombosis.
Finally, in Chapter 7, a study on the occurrence of symptomatic venous 
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Travel and venous thrombosis: 
a systematic review
S. Kuipers, A.J.M. Schreijer, S.C.Cannegieter, H.R.Büller, F.R.Rosendaal, S.Middeldorp
Journal of Internal Medicine. 2007 Dec; 262(6): 615-34
Abstract
In the past decade, numerous publications on the association between venous 
thrombosis (VT) and travel have been published. Relative and absolute risks 
of VT after travel, and particularly after travel by air, have been studied in case-
control and observational follow-up studies, whereas the effect of prophylaxis has 
been studied through intervention trials of asymptomatic clots. The mechanism 
responsible for the association between travel and VT was addressed in 
pathophysiologic studies. Here, we systematically reviewed the epidemiologic and 
pathophysiologic studies about the association between travel and VT. 
 We conclude that long distance travel increases the risk of VT 
approximately 2-4 fold. The absolute risk of a symptomatic event within 4 weeks of 
flights longer than 4 hours is 1/4600 flights. The risk of severe pulmonary embolism 
occurring immediately after air travel increases with duration of travel, up to 4.8 per 
million in flights longer than 12 hours. The mechanism responsible for the increased 
risk of VT after (air) travel has insufficiently been studied to draw solid conclusions, 
but one controlled study showed evidence for an additional mechanism to 
immobilization that could lead to coagulation activation after air travel.
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Introduction
Venous thrombosis is a serious disease that affects approximately 2-3 per 1000 
persons per year (1;2). Both genetic and environmental factors are known to 
increase the risk of venous thrombosis and these are mainly associated with 
procoagulant changes of the blood or immobilization. Prevalent genetic risk 
factors for venous thrombosis are the factor V Leiden mutation (3) and the 
prothrombin G20210A mutation (4), each present in several percent of the 
population. Environmental factors that increase the risk of venous thrombosis 
include oral contraceptive use, pregnancy, recent surgery, major trauma, 
immobilization and malignant diseases (5). In the last decade, it has become clear 
that long distance travel increases the risk of venous thrombosis as well.
 The first four cases of venous thrombosis associated with air travel were 
described in 1951 (6). Since then, many case-reports and case-series have been 
published on venous thrombosis associated with not only air travel, but also 
travel by train, bus or car and even tractor driving (7). The term economy class 
syndrome was coined in 1977 (8) and the first controlled study was published in 
1986. Sarvesvaran and colleagues studied causes of death occurring at a large 
international airport and concluded that pulmonary embolism occurred more often 
in the arrival hall than in the departure hall (9). More controlled studies were not 
conducted until a young woman died of pulmonary embolism at Heathrow airport 
in 2000. Since then, numerous reports have published results of case-control, 
follow-up and intervention studies on the association between air travel and 
venous thrombosis. Furthermore, several studies have looked into the mechanism 
responsible for venous thrombosis after air travel. A number of investigators have 
studied the effect of prolonged immobilization with or without the combination with 
flight-related factors, such as hypobaric hypoxia or dehydration.
 The objective of this systematic review is to quantify the risk of venous 
thrombosis after long distance travel, when possible to assess the effect of various 
prophylactic measures on this risk and to summarize the available literature 
about potential mechanisms of the association between air travel and venous 
thrombosis. 
Methods
A systematic literature search was performed to identify all studies that included 
data on long distance travel and venous thrombosis. Studies that included 
epidemiological data on absolute and relative risks of venous thrombosis 
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after any kind of travel, randomized controlled trials that assessed the effect 
of prophylactic measures and publications that described pathophysiological 
studies were included.
Search strategy
Publications were identified through an extensive search, using PubMed, Embase, 
Web of Science and the Cochrane Central Register of Controlled Trials. We did 
not apply a language restriction and searched all databases until January 1st 2007. 
Two reviewers independently screened the titles of all retrieved records for obvious 
exclusions. The same two reviewers read all remaining abstracts to identify eligible 
studies. Differences were solved by discussion.
Exposures of interest and outcomes
The main exposure of interest was travel, irrespective of mode of transportation 
and duration of travel. Studies that assessed the effect of prolonged 
immobilization and hypobaric hypoxia were evaluated as well. The main outcome 
of interest was symptomatic deep vein thrombosis and pulmonary embolism, 
diagnosed by objective methods (ultrasound, venography, ventilation-perfusion 
scanning, spiral ct-scanning, angiography or at autopsy). We also considered 
asymptomatic venous thrombosis (diagnosed by objective methods), although 
of unclear clinical significance, and the effect of prophylactic interventions. The 
effect of any of the exposures of interest on coagulation parameters was the main 
outcome in the pathophysiological studies.
Quality assessment
All studies were judged on both internal and external validity by 2 reviewers 
independently, according to guidelines of the Cochrane Collaboration Handbook 
(10). Disagreement was solved by discussion and when no consensus could be 
reached a third reviewer was consulted. 
 We considered case-control studies to have a low risk of bias (i.e. to have 
a good internal validity) when selection-bias of cases and controls was unlikely 
(when they came from the same population and travel frequency did not influence 
the likelihood of inclusion in the study), when travel frequency was assessed in the 
same way in cases and controls, when recall bias was minimized, when venous 
thrombosis was diagnosed by objective means and when cases were consecutive, 
unselected patients with a first thrombotic event.
 Follow-up studies that assessed the risk of venous thrombosis in groups 
of travellers were considered to have a low risk of bias when loss to follow-up was 
less than 10%, when details of the exposure of interest were mentioned (mode 
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of transportation, duration of travel, number of flights) and when the outcome 
of interest was assessed in the same way in all study participants. Symptomatic 
venous thrombosis had to be diagnosed by objective methods as described above.
 Intervention studies were included when they assessed the effect of 
prophylactic measures on the risk of venous thrombosis (both symptomatic 
and asymptomatic). They were considered to have a low risk of bias when 
randomization procedure and allocation concealment were adequate, when 
outcome assessors were blinded for the exposure status of the participants 
and when loss to follow-up was described and less than 10%. Ideally, study 
participants were blinded as well. 
 We included pathophysiological publications when they contained original 
data on studies on the effect of either travel, or one of its specific factors (such 
as immobilization or hypobaric hypoxia), on thrombin generation or fibrinolysis in 
humans. Ideally, pathophysiological studies assessed the effect of an exposure of 
interest as compared to a control situation that would be exactly the same as the 
exposure situation except for the exposure itself. This would rule out other effects, 
such as circadian rhythm.
Data extraction:
 For epidemiological studies, we used standardized forms for extraction of 
the following data:
- Case-control studies: source population of cases and controls, number of 
cases and controls, methods of diagnosis, disease characteristics (types 
of thrombotic events that were included), general characteristics of cases 
and controls (age, sex, prevalence of risk factors for venous thrombosis), 
frequency of travel in both study groups and when possible mode of 
transportation, duration of travel and time interval between travel and 
event or index date.
- Follow-up studies: method of selection and inclusion of the study 
participants, numbers of participants (when applicable per subgroup), 
presence of a non-travelling control population, general characteristics 
(age, sex, prevalence of other risk factors for venous thrombosis), 
outcome assessment, frequency of all relevant outcomes (symptomatic 
venous thrombosis and asymptomatic thrombi), numbers lost to follow-up.
- Prophylactic intervention studies: method of recruitment of participants, 
details of the treatment (type of stockings, dosage and frequency of any 
pharmacological treatment), use of placebo, method of randomization, 
concealment of allocation, method of outcome assessment, frequency 
of all relevant outcomes per treatment group, occurrence of adverse 
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outcomes per treatment group (such as hemorrhagic complications when 
antithrombotics were studied), numbers lost to follow-up.
- Pathophysiological studies: general characteristics, presence of a 
control population, intervention (immobilization, hypobaric hypoxia or 
travel), outcomes, assessment of outcome of interest (methods and 
timing), main results.
Statistical analysis
All reported odds ratios from case-control studies were extracted. When possible, 
we pooled odds ratios to estimate relative risks for both air travel and travel by 
other modes of transportation. Pooling was performed using the inverse-variance-
weighted average of the log odds ratios from the individual studies.
 From follow-up studies, we calculated the absolute risk of symptomatic 
venous thrombosis per flight. We also calculated the risk of asymptomatic thrombi 
per flight. When possible, we calculated incidence rates of venous thrombosis 
within a few weeks after a long haul flight. When data on different modes of 
transportation and duration of travel were available, we calculated risks per 
flight and incidence rates for each mode of transportation and duration of travel 
separately. We did not attempt to pool the data from follow-up studies, because of 
anticipated differences in study design and participants.
From prophylactic intervention studies, we calculated absolute risks of 
thrombotic events per flight per intervention group. Furthermore, relative risks 
of the treated groups versus the control groups were calculated and, when 
possible, data were pooled. To assess heterogeneity, we calculated the I2-statistic. 
This describes the percentage of the variability in effect estimates that is due to 
heterogeneity rather than chance. We considered heterogeneity present when I2 
was greater than 50%. 
Due to the diversity of the study designs, no attempt to pool data for 
pathophysiological studies was made.
Results
At the first search we found a total of 4154 titles. Based on the title, 3626 papers 
were excluded. We screened the abstracts of 528 publications, after which 10 
publications with case-control data, 20 papers describing observational follow-up 
studies, 11 reports on intervention studies, 113 with case-reports or small case-
series and 14 describing studies on the possible mechanism causing venous 
thrombosis after long distance travel were identified (Figure 1). The remaining 
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publications were comments, reviews, letters or editorials or did not concern 
venous thrombosis and long distance travel.
Figure 1. Results of the literature search
*  These publications were editorials, reviews or comments or did not concern travel-related thrombosis.
Case-control studies – estimate of relative risks
We identified ten publications in which travel frequency of cases with symptomatic 
venous thrombosis was compared to a control population without venous 
thrombosis (Table 1) (11-20). One publication was excluded because the data 
were also used in a subsequent more extensive publication (16). There were 4 
studies with an increased potential of bias. In one study, cases were self-reported, 
without verification of the diagnosis and both cases and controls were selected 
frequent travellers (13). In 3 studies, individuals with suspected venous thrombosis 
in whom the diagnosis was ruled out were used as control persons (11;15;20), 
which may have caused overrepresentation of travel exposure in the controls 
and thus underestimation of the effect of travel. In these studies with a potential 
of bias, the odds ratios for any travel ranged from 0.5 to 1.3, whereas in the 
other studies, the odds ratios ranged from 1.8 to 4.0 (12;14;17-19). The pooled 
odds ratio of all studies together was 1.7 (CI95 1.4-2.1). After exclusion of the 4 
studies with a high potential bias, this increased to 2.3 (CI95 1.8-2.9). Six studies 
contained data on air travel only or separately for air travel and other modes of 
travel (11;12;15;17;18;20). The pooled odds ratio for air travel of any duration of all 
studies was 1.4 (CI95 0.9-2.0). After exclusion of three studies with a potential bias 
(11;15;20), the pooled odds ratio of the remaining studies (12;17;18) was 1.9 (CI95 
1.2-2.8). Three publications showed data on long distance air travel (17;18;20), 
defined as flights longer than 8 hours, with odds ratios ranging from 1.3 to 7.9 
and a pooled odds ratio of 1.9 (1.1-3.6). After exclusion of one study with a high 
potential bias (20), this pooled odds ratio increased to 3.9 (CI95 1.4-10.7).
19Travel and Venous Thrombosis: a systematic review






















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Observational follow-up studies – estimates of absolute risks
Twenty publications reported data on observational follow-up studies (13;18;21-
38). Two publications (22;34) contained data that were also used in another 
publication (27;33). From three studies, no absolute risks could be calculated, 
because either the number of events or the number of flights was not provided 
(13;28;36). Of one paper (24), no full text version could be retrieved. The 
remaining 14 publications are listed in Table 2. 
 Six publications concerned studies in which passengers were 
systematically screened for the presence of asymptomatic venous thrombosis 
after a long haul flight (21;23;27;29;37;38). In one study, the methods were 
inadequately described (23) and in another, the follow-up was incomplete (29). 
The risk of mainly asymptomatic thrombosis in air travellers as found by screening 
ranged from 0% (no events in 160 passengers) to 1.5% (11 events in 744 
passengers). Only two studies included a non-travelling control population (37;38). 
In the first study, none of the 160 control persons developed a thrombus and in 
the second study, 2 out of 1213 (0.2%) non-travelling participants developed deep 
vein thrombosis. 
 The absolute risk of symptomatic venous thrombosis was assessed 
in a study of approximately 9000 employees of international companies and 
organizations (32). A total of 22 events occurred within 8 weeks of flights longer 
than 8 hours, yielding an absolute risk of symptomatic venous thrombosis of 215 
per million travellers (CI95 133-316 per million) after flights longer than 4 hours. 
This was equivalent to a risk of 1/4600 flights. The risk increased with travel 
duration, up to 793 (CI95 198-1784) per million travellers after flights longer than 
16 hours. The results of this study may not be generalisable to all travellers, since 
the study was conducted in a healthy, working population. 
 One retrospective follow-up study (25) assessed the frequency of deep 
vein thrombosis in high risk surgical patients that had to travel long distances 
prior to their operation and found a risk of 4.9% (CI95 2.1-7.8) within 2 weeks of 
the operation, as compared to 0.2% (CI95 0.1-0.2%) in patients undergoing the 
same types of high-risk surgery without prior air travel. In this study, the use of 
prophylaxis for thrombosis was unclear and travelling and non-travelling study 
participants came from different source populations, because the non-travellers 
were all US citizens, whereas all travellers were non-US citizens visiting the 
country for the surgical procedure. 
21Travel and Venous Thrombosis: a systematic review























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Three studies assessed the risk of pulmonary embolism, requiring medical care 
immediately after long distance air travel (26-28;33;35;38). Two studies found a 
dose-response relationship between the frequency of pulmonary embolism and 
duration of travel (33;35). In one study, the risk ranged from no events in 74.2 
million flights shorter than 3 hours to 13 in 2.7 million flights (4.8 per million, CI95 
2.2-7.4 per million) in flights longer than 12 hours (33). In a similar Spanish study, 
no PE was seen after 28.0 million flights shorter than 6 hours and in 9.1 million 
flights longer than 8 hours, 15 cases of severe pulmonary embolism occurred 
(absolute risk 1.7 per million, CI95 0.8-2.5) (35). In another study using a similar 
design, the risk of PE immediately after a flight longer than 9 hours was 2.6 per 
million (CI95 1.4-3.8 per million) (26). In all three studies, the time window in which 
a traveller could become a case was extremely small, since only persons that 
developed severe symptoms immediately after arrival were included. 
 One study assessed the risk of hospital admission for pulmonary 
embolism within 2 weeks of international flights to Australia, which was found to 
be 9.6 per million (CI95 7.0-12.6 per million) for 4.9 million passengers who were 
residents of Australia and 43.5 per million (CI95 37.5-49.8 per million) for 4.6 
million passengers who were visiting Australia (30). In this study, travellers who 
died before reaching the hospital or patients who were treated ambulatory were 
not included, which may partly explain the difference between residents and non-
residents of Australia. 
 The risk of fatal pulmonary embolism after air travel was assessed in 2 
studies (18;31). One study found no fatal PE’s in 1.1 million passengers arriving 
after international flights to Charlotte-Douglas airport, Charlotte, NC in the US, 
whereas another study found 11 cases of fatal PE within 4 weeks of 19.3 million 
flights longer than 3 hours, yielding an absolute risk of 0.6 per million passengers 
(CI95 0.2-0.9 per million). In both studies, patients who were not sent to the study 
hospital were missed.
 
Randomized controlled trials – estimate of the effect of interventions 
A total of 11 randomized trials were conducted to assess the effect of various 
prophylactic measures on the risk of venous thrombosis after air travel (23;39-
48). The main results of these trials are shown in Table 3. All studies had a similar 
design: a number of air travellers, varying from 148 to 833, making long haul 
flights (>7 hours) were randomized to either a control group or an intervention 
group that received elastic compression stockings, aspirin, heparin, venoruton 
(hydroxyethylrutosides), pycnogenol (pine tree extract containing procyanidins, 
bioflavonoids and organic acids) or FLITE tabs (containing pycnogenol and 
nattokinase, a soy bean extract). All passengers were routinely screened for venous 
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thrombosis by ultrasound after their flight (within a maximum of 48 hours). All 
but one of these studies were conducted by the same research group. In these 
publications, the methods of the study were inadequately described or even 
contradictory. Most striking was that in- and exclusion criteria were frequently 
overlapping. Furthermore, the method of recruitment of participants and whether 
study participants and outcome-assessors were blinded for the treatment group 
was unclear. The majority of the thrombotic events in all trials were asymptomatic, 
which may partly explain the high prevalence in the control population. The number 
of symptomatic events was not clearly described, but is likely to be much lower. 
These drawbacks, as well as a report from the Medical research Counsil’s Fitness 
to Practice Panel (49), judging it proved that these papers named co-authors who 
had not approved the papers, hamper the credibility of these trials. We therefore 
will not discuss the results of these trials in this systematic review. In the only 
remaining trial (48), the effect of elastic compression stockings was assessed in 
231 airline passengers travelling at least 8 hours. None of the 100 passengers who 
were randomized to the elastic compression stockings group developed venous 
thrombosis, whereas 12 of the 100 control passengers did, yielding a relative risk 
of 0.04 (CI95 0-0.6). However, 4 passengers wearing elastic compression stockings 
developed superficial thrombophlebitis, whereas none of the control passengers did.
Mechanism of travel related thrombosis
There are several explanations for the increased risk of venous thrombosis after air 
travel. Apart from immobilization, flight specific factors, such as hypobaric hypoxia 
may affect the coagulation system. Various investigators have examined the effect 
of air travel, or one of its specific aspects (e.g. immobilization and hypobaric 
hypoxia) on thrombin generation and fibrinolysis. 
 The studies differed much in participant characteristics, duration of 
exposure, type of exposure and statistical analyses. Most studies determined 
changes in various parameters before and after specific exposures in volunteers. 
Table 4 summarizes the relevant aspects of the studies and the direction of the 
changes in the most commonly used coagulations parameters during thedifferent 
exposures.
25Travel and Venous Thrombosis: a systematic review
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Parameters of thrombin generation and fibrinolysis
Thrombin generation and fibrinolysis are regulated by its activators and inhibitors 
(Figures 1 and 2). The amount of thrombin generated is often assessed by levels 
of activation peptide prothrombin fragment 1+2 (F1+2), and its inhibitor complex 
thrombin-antithrombin (TAT). Activation of the fibrinolytic system is reflected by 
increased levels of D-dimers (fibrin degradation products), which by definition also 
points to thrombin generation and hence may be its simple consequence (50).
Increased levels of activated coagulation factors (such as FVIIa and FVIIIa) 
are also known to increase thrombin generation (50;51).
Figure 2. Thrombin generation*
*   Dashed lines reflect inhibition, solid lines reflect activation, and substances in italic are products of the process. 
Figure 3. Fibrinolysis*
*  Dashed lines reflect inhibition, solid lines reflect activation.
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XIa
Activated protein C +  Protein SIXa + VIIIa 
TF-VIIa Xa+Va           Trombin (IIa)                    Fibrin
F1+2
TAT 
Tissue factor pathway inhibitor
Antithrombin
Urokinase type plasminogen activator





Fibrin Fibrin degradation products 
(e.g. D-dimer)
Immobilization
The most obvious explanation for air travel related thrombosis is immobilization. 
Passengers are restricted to limited space, resulting in a cramped position during 
long haul flights and are even more immobilized when they are asleep. 
Several studies investigated the effect of prolonged immobilization on 
thrombin generation, but conflicting results were shown (52-65) (Table 4). Stricker 
et al. found a decrease in markers of thrombin generation during 6-hours of 
immobilization in 40 volunteers, whereas they found no change in 18 participants 
during the ambulant situation (61). In a subsequent study with a similar design, 
the investigators found similar results in 20 volunteers and also found evidence for 
down-regulation of the protein C system, one of the inhibitors of the coagulation 
system (62). Others found evidence for thrombin activation during a 10-hour bus 
journey in a group of 19 healthy volunteers (58). In a similar study, but with 23 
elderly with varicose veins, TAT increased after a 16-hour bus trip (especially in 
two high responders), indicating thrombin generation. However, F1+2 remained 
unchanged after the bus trip and FVIIa decreased (64). The same study group 
found no difference in a comparable study in markers of thrombin generation 
between 31 bus travellers and a non travelling control group (n=9). More recently, 
Ansari et al. found no change in markers of thrombin generation in 10 healthy 
volunteers after 8 hours of prolonged sitting, although F1+2 levels showed a 
tendency to decrease (52). In an artificial model of immobilization, with 30 min of 
blood stasis provoked by a pressure cuff around the thigh, F1+2 decreased (66). 
The effect of immobilization on the fibrinolytic system was also contradictory 
(Table 4). In some studies, markers of fibrin generation and fibrinolysis remained 
unchanged (61;62;64;66). Others found a decrease in levels of tPA (an activator 
of the fibrinolytic system) and PAI (an inhibitor of the fibrinolytic system). D-dimers 
remained unchanged in this study, with the exception of two subjects in whom 
D-dimers increased (>0,5 mg/l) (58). In a more recent study, PAI decreased after 8 
hours of immobilization, whereas D-dimer and tPA levels did not clearly differ from 
baseline, although both parameters had a tendency to decrease (52).
In the majority of the studies, no control population was used to assess 
whether any observed effect was the result of immobilization or other factors, such 
as circadian rhythm. Only in one study, coagulation parameters in passengers 
after an 8-hour bus trip were compared to those in a non-travelling control 
population (64). No differences in TAT, D-dimers or F1+2 were observed between 
the two groups. 
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Hypoxia during simulated air travel 
During air travel, cabin pressure drops to 75.8 kPA, which is equivalent to an 
altitude of 2400 meters above sea level. Consequently, oxygen saturation can 
drop as low as 90-93% and even to 80% in passengers who are asleep (67;68). 
To separate the effect of sole hypoxia from hypobaric hypoxia, both the effects 
of hypobaric as well as normobaric hypoxia on human coagulation have been 
investigated.
Already in 1976, Maher et al. studied the effect of acute hypobaric hypoxia 
(corresponding to an altitude of 4400 meters above sea level) on human coagulation 
(69). He found a shortening of the partial thromboplastin time (aPTT) after 1 hour 
and 24 hours in a hypobaric chamber whereas fibrinogen and FVIII levels returned 
to baseline at 24 hours after an abrupt decrease after 1 hour. Fibrin degeneration 
products (e.g. D-dimers) were transiently increased in three subjects. 
Years later, when more laboratory assays became available, the effect 
of hypoxia on both thrombin generation and fibrinolysis was further investigated 
(Table 4). Bendz et al. exposed 20 volunteers to 8 hours of hypobaric hypoxia (76 
kPa) by natural elevation and found an increase in thrombin generation (reflected 
by TAT and F1+2), with a maximum increase after 2 hours of hypobaric hypoxia 
(53). These changes were accompanied by an increase in FVIIa (measured as 
FVIIa-tissue factor complex), while FVII antigen and TFPI (antigen and activity) 
decreased. However, in a controlled experiment with eight participants, Crosby 
et al. found no evidence for thrombin generation during exposure to 8 hours of 
isocapnic hypoxia compared to 8 hours of normobaric normoxia (55). Also short 
term exposure to normobaric hypoxia did not seem to affect markers of thrombin 
generation in a cross over study (56). In a much larger study, Toff and colleagues 
exposed 73 volunteers alternately to hypobaric hypoxia and normobaric normoxia. 
They found no difference between the changes in markers of thrombin generation 
during hypobaric or normobaric exposures (65). These findings were confirmed by 
Schobersberger and colleagues (59). 
Markers of fibrinolysis mainly remained unchanged during hypoxia in most 
studies (53;55;56;65), although Schobersberger found a decrease in t-PA after 10 
hours of hypoxia (59).
Air travel
Only few studies have investigated the effect of actual air travel on the coagulation 
system (Table 4). No evidence for increased thrombin generation was found 
in a study with 20 volunteers (including 10 volunteers who were obese, aged 
>40 years, used oral contraceptives or had venous insufficiency) after a return 
flight from Vienna to Washington (57). In a similar study, Boccalon et al. found 
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a reduction in thrombin generation after an 11-h return flight with 30 healthy 
male volunteers (54). In a tightly controlled crossover study with 71 volunteers 
(including 41 women with risk factors for venous thrombosis, i.e. factor V Leiden 
mutation, oral contraceptive use or both) evidence was found for thrombin 
generation in 17% of individuals during an 8-h flight, whereas this was found in 
only 3% during an 8-h movie marathon and in 1% during the ambulant situation. 
The effect was most evident in women with FVL who use oral contraceptives (60). 
 Schobersberger et al. found evidence for suppressed fibrinolysis during 
air travel (57), whereas markers of fibrinolysis remained unchanged in the study 
by Boccalon et al (54). In the crossover study, the fibrinolytic system was activated 
in more participants during the flight then during the immobilized or ambulant 
situation (60).
Drawbacks of the studies
Thus, the results in all three settings (immobilization, hypoxia and air travel) were 
conflicting. There are several possible explanations for these discrepancies. Firstly, 
since it is plausible that only some individuals are susceptible to coagulation 
activation during air travel, people with risk factors for venous thrombosis may 
react differently than those without. In order to control for the large inter-individual 
normal range of coagulation parameters, data are best analyzed on an individual 
level in a crossover design. Most studies that have been conducted so far 
included few participants (mostly without risk factors for venous thrombosis) and 
presented data on group level only. Secondly, when only pre- and post exposure 
data are compared, effects of circadian rhythm are not accounted for. Only 
four studies compared changes in coagulation parameters during air travel or 
hypobaric hypoxia to a control situation and may be considered to have yielded 
valid data (55;56;60;65).  
Discussion
Long distance travel increases the risk of venous thrombosis 2-4 fold. Only one 
study assessed the risk of symptomatic venous thrombosis in a frequently travelling 
working population and found a risk of 1/4600 travellers within 4 weeks of flights 
longer than 4 hours. The risk of pulmonary embolism occurring immediately after 
air travel increases with duration of travel, from 0 in flights shorter than 3 hours up 
to 4.8 per million in flights longer than 12 hours. The risk of fatal PE immediately 
after arrival, which was assessed in two studies, is estimated at less than 0.6 per 
million passengers in flights longer than 3 hours. The risk of venous thrombosis is 
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not increased after travel shorter than 3-4 hours. The risk of asymptomatic venous 
thrombosis after long haul flights ranged up to 12%.
 In one randomized controlled trial comparing the prevalence of 
asymptomatic venous thrombosis in control travellers to that in travellers assigned 
to wear stockings, stocking effectively prevented the development of asymptomatic 
thrombi. The effect of stockings, low molecular weight heparin and aspirin has 
been studied in a series of trials by the same research group. These studies 
had serious methodological flaws and the scientific integrity of the authors was 
questioned by the Medical Research Councils Fitness to Practice Panel (49-51). 
 Although several studies have addressed the mechanism responsible for 
the association between venous thrombosis and long distance travel, differences 
in design, analysis and interventions do not allow us to draw solid conclusions. 
One controlled study that included volunteers with risk factors for venous 
thrombosis showed evidence for an additional mechanism to immobilization 
that could lead to coagulation activation after air travel, especially in susceptible 
individuals.
 Future research should focus on the mechanism responsible for 
coagulation activation due to (air) travel, identification of individuals at high 
risk, and prophylactic measures that prevent symptomatic venous thrombosis 
and outweigh its potential harms. Based on the currently available evidence, 
we conclude that the absolute risk of symptomatic venous thrombosis in the 
general travelling population is not high enough to justify the widespread use of 
prophylaxis, in particular of prophylaxis that may cause side effects. There may be 
a rationale for preventive measures in individuals at high risk, but it is currently not 
known which prophylactic measures have a positive balance of effect and risk.
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Chapter 3
Use of preventive measures 
for air travel-related venous 
thrombosis in professionals who 
attend medical conferences
S. Kuipers, S.C.Cannegieter, S.Middeldorp, F.R.Rosendaal, H.R.Büller
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Abstract 
Background: Clear guidelines for the use of prophylaxis for air travel-related 
venous thrombosis are not available. 
 Objectives: To assess the use of preventive measures for air travel-related 
venous thrombosis in professionals employed in the field of thrombosis and 
haemostasis and in other fields. 
 Methods: We performed a survey amongst delegates of the XXth 
ISTH Congress, the 15th ISDB Congress and the 13th Cochrane Colloquium, 
which all took place in Australia 2005. All delegates received a questionnaire 
with questions on personal and travel details, risk factors for thrombosis and 
preventive measures taken. 
 Results: 2089 questionnaires were completed (response 53%). Overall, 
80% of the respondents used preventive measures. Low molecular weight 
heparin and vitamin K antagonists were mostly used by ISTH delegates (10%, 
as compared to 1% by delegates of the other conferences). Aspirin was used by 
20% of the ISTH delegates and by 21% of the other delegates. Medical doctors 
used more pharmacological prophylaxis (31%) than research fellows (11%) and 
non-clinical scientists (22%). Dutch (64%) and Asian respondents (67%) least 
used any form of prevention, whereas Israeli used most (94%). Subjects with risk 
factors for venous thrombosis more often used prophylaxis (90%) as compared 
to those without (77%). In a multivariate analysis, the conference attended, 
nationality, age, the presence of risk factors and professional background were 
determinants of prophylaxis use, while seating class was not.
 Conclusion: The use of prophylaxis for air travel-related venous 
thrombosis varied between conferences, professional backgrounds and 
countries. These differences stress the need for clear guidelines on prevention of 
air travel-related venous thrombosis.
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Introduction
Travel- related venous thrombosis (VT) has received major media-attention 
since a young woman died of pulmonary embolism at Heathrow airport 
after a flight from Australia in 2000. Several controlled studies on air travel-
related thrombosis showed a 2- to 4-fold increased risk of thrombosis after air 
travel1-6 and an increasing incidence of venous thrombosis with the distance 
travelled7-8. For advice to travellers, the absolute risk is relevant, but only limited 
information is available so far. The risk of severe pulmonary embolism was 
found to be 4.7 per million passengers after flights longer than 10.000 km7. 
Another study showed a risk of fatal pulmonary embolism of 1.3 per million 
passengers travelling for at least eight hours9. In 3 follow up studies, the risk 
of mainly asymptomatic venous thrombosis was found to be several percent10-
12. The absolute risk of symptomatic venous thrombosis after air travel must 
lie somewhere between the extremes of asymptomatic venous thrombosis 
and severe pulmonary embolism. In a large follow up study amongst 9000 
employees of international companies and organizations, we found the 
absolute risk of VT within 4 weeks of flights longer than 4 hours to be 1/6000 
flights13. Large randomized trials on preventive measures for symptomatic air 
travel-related VT have not been conducted and therefore clear guidelines are 
not available. A media-hype combined with lack of knowledge of the actual 
risk of developing VT after air travel may lead to excessive use of potentially 
dangerous precautions, such as anticoagulant therapy.
The objective of this study was to assess the use of preventive measures 
for air travel-related thrombosis in professionals, either working in the field of 
haemostasis and thrombosis or in other areas.
Methods
To assess the use of preventive measures for air travel-related venous thrombosis 
we sent questionnaires to all delegates of the XXth Congress of the International 
Society on Thrombosis and Haemostasis (ISTH), held in Sydney in August 
2005, to those of the 15th International Society of Developmental Biology (ISDB) 
Congress, held in Sydney in September 2005, and to those of the 13th Cochrane 
Colloquium (on the production, dissemination and use of systematic reviews), 
which took place in Melbourne in October 2005. 
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Questionnaire
All delegates of the three congresses for whom a correct e-mail address was 
available received an e-mail with an explanation about the study and a link to a 
short on-line questionnaire.
 In the questionnaire, we asked questions about 1) general demographic 
data (age, sex, professional background and country of residence), 2) the 
flight to the conference (mode of travel, total duration and duration of longest 
uninterrupted leg, class of travel), 3) risk factors for thrombosis (personal 
history, presence of thrombophilia, active cancer, recent surgery, varicose veins, 
estrogen use and pregnancy or puerperium), 4) in-flight behavior (sleeping, 
use of sleeping medication, alcohol-use and non-alcoholic consumptions) and 
5) preventive measures for air travel-related thrombosis (walking at least once 
every 2 hours, exercises as suggested in in-flight magazines or videos, elastic 
compression stockings, aspirin, low molecular weight heparin (LMWH) or vitamin 
K antagonists (VKA)). The questions in the questionnaire only covered travel 
to Australia, not the return-flight. About 2-3 weeks after the initial e-mail, a first 
reminder was sent, followed by a second after 5-6 weeks.
Statistical analysis 
For each type of preventive measure, percentages of use were calculated. Ninety-
five percent confidence intervals for differences of proportions were based on 
binomial distributions. Subgroups were defined based on the conference that was 
attended, professional background, nationality, risk factors for venous thrombosis 
and class of travel. Delegates of the conference on thrombosis and haemostasis 
were compared to delegates of the other 2 conferences. Medical doctors were 
compared to non-clinical scientists (mainly biologists and biochemists), research 
fellows (post-graduate students and PhD students) and individuals with a different 
professional background (such as employees of pharmaceutical companies and 
policy makers). Medical doctors who were also doing PhD research project were 
only counted as medical doctors. To assess differences between nationalities, 
countries with a high number of respondents were analyzed as such (USA, 
Canada, UK, Netherlands, Germany, France, Italy and Israel). Inhabitants of 
Scandinavian countries (Denmark, Sweden, Norway and Finland) were analyzed 
together, because there were no major differences in in-flight behavior and use 
of preventive measures between these countries. Citizens from Asian countries 
were grouped as well, because of the small numbers per country. Inhabitants 
of Australia and New Zealand were excluded from the analyses because their 
duration of travel was unlikely to be extreme. To study the effect of risk factors, all 
risk factors mentioned in the questionnaire were analyzed separately. Furthermore, 
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individuals with any risk factor (personal history of venous thrombosis, presence 
of thrombophilia, active cancer, recent surgery, varicose veins, pregnancy and 
puerperium) were compared to individuals with none of the risk factors, which latter 
group included those using estrogens. 
 Because many variables were associated, such as age, profession and 
class, we performed a logistic regression analysis to determine which factors 
were the strongest determinants of prophylaxis. Whether or not pharmacological 
prophylaxis was taken (both in- and excluding aspirin) was used as outcome 
measure. Age (split in 5 categories), sex, country, professional background, 
presence of risk factors and class of travel were entered as independent variables 
in the regression model.
Results
2941 delegates of the XXth ISTH conference, 672 of the ISDB congress and 445 
of the Cochrane Colloquium received the invitational e-mail with a link to the 
questionnaire. After exclusion of inhabitants of Australia and New Zealand, a total 
of 3939 eligible delegates remained. The responses were 63% (ISTH, n=1638), 
26% (ISDB, n=170) and 69% (Cochrane, n=281). The overall response was 
57%. General characteristics of the responders are shown in Table 1. Overall, 
59% of the respondents were men (n=1198). Almost half of the delegates of the 
ISTH conference were medical doctors (43%, n=703), as compared to 5% (n=9) 
at the ISDB conference and 26% (n=74) at the Cochrane Colloquium. Almost 
all respondents (99%, n=2049) had travelled by air to the conference. Most 
delegates (70%, n= 1442) of the delegates had travelled for 20 hours or more 
and 1627 (79%) respondents had at least one flight longer than 10 hours. The 
mean duration of travel did not differ between delegates of the three conferences. 
Delegates of the ISTH conference travelled more frequently in business or first 
class than delegates of the other two conferences (29% vs 9%). The respondents 
came from 69 different countries with most delegates at all three conferences 
coming from the United States (n=405) and the UK (n=306). The distribution 
over the represented continents was approximately equal in the ISTH compared 
to the other two conferences.
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Table 1 General Characteristics of the respondents of the three conferences
Characteristic ISTH (1638)            ISDB (170) Cochrane (281) Total (2089)
N % N % N % N %
Age distribution:
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*   Austria, Belarus, Belgium, Bulgaria, Croatia, Czech Republic, Estonia, Greece, Hungary, Lithuania, Luxemburg, Poland,  
Portugal, Romania, Russia, Slovak Republic, Slovenia, Spain, Switzerland, Turkey and Ukraine.
**  Cambodia, China, India, Indonesia, Japan, South-Korea, Malaysia, Pakistan, Philippines, Singapore, Sri Lanka, Taiwan, Thailand 
and Vietnam
Overall use of preventive measures 
The overall use of preventive measures is shown in Table 2. 1577 delegates 
(80%, CI95 78-81%) used some kind of preventive measure, of whom 509 (26%, 
CI95 24-28%) delegates used medication to prevent air travel-related thrombosis 
(aspirin, LMWH or VKA). Stockings were used by 344 respondents (17%, CI95 16-
19%). 1466 delegates (74% CI95 72-76%) did exercises or walked around at least 
once every 2 hours.
Use of preventive measures for air travel-related venous thrombosis in professionals who attend medical conferences44
Use of preventive measures per conference
The use of preventive measures varied considerably per conference. Delegates of 
the ISDB conference least used any type of preventive measure. Anticoagulants 
(LMWH, VKA or aspirin) were used by 27% (n=413) of the professionals in the 
field of thrombosis and haemostasis, compared to 21% (n=96) at the other 2 
conferences (difference 6%, CI95 1-10%). LMWH and VKA were used almost 
exclusively by delegates of the ISTH conference (10%, n=121), while this was 
1% at the other 2 conferences combined (difference 9%; CI95 7-11%). Aspirin 
was used mostly by delegates of the Cochrane Colloquium (29%, n=80) as 
compared to delegates of the ISTH conference (20%, n=313, difference 9%, CI95 
3-14%). Stockings were also most worn by delegates of the Cochrane colloquium 
(27%, n=75) as compared to the ISTH conference (17%, n=255, difference 
10%, CI95 5-16%) and the ISDB conference (8%, n=14, difference 19%, CI95 12-
25%). Regular exercises and walking were practiced mainly by delegates of the 
Cochrane colloquium as well.
Use of preventive measures by professional background
Use of preventive measures per occupation is shown in Table 2. Research fellows 
least used any kind of preventive measure (74%, n=134). It should be noted that 
research fellows were younger and had less risk factors for venous thrombosis 
than medical doctors, non-clinical scientists and those with other professional 
backgrounds  Pharmacological prophylaxis was used most by medical doctors 
(31%, n=233) and individuals with a professional background other than medical 
doctor, research fellow or non-clinical scientist (31%, n=111). LMWH and VKA 
were used predominantly by medical doctors (14%, n=86). Aspirin was taken 
most by the delegates with other professional backgrounds (28%, n=99). 
Stockings were used by approximately 20% of the medical doctors (n=150) and 
delegates with other professional backgrounds (n=76). Twelve percent (n=22) 
of the research fellows and 14% (n=96) of the non-clinical scientists wore elastic 
compression stockings. The percentages of individuals doing exercises or 
walking did not vary much between professional backgrounds. 
Use of preventive measures by country
The use of preventive measures varied remarkably per country, which is shown 
in Table 2. Inhabitants of the Netherlands (64%, n=93) and people originating 
from Asia (67%, n=167) least frequently used any measures to prevent air 
travel-related thrombosis, whereas the inhabitants of Israel used most (94%, 
n=19). Pharmacological prophylaxis (aspirin, LMWH or VKA) was used most by 
inhabitants of Germany (35%, n=52), the USA (33%, n=129) and the UK (33%, 
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n=97). LMWH or VKA was used mainly by inhabitants of Israel (22%, n=4) and 
Germany (16%, n=24). Aspirin was used by 32% (n=92) of the respondents from 
the UK, by 31% (n=119) of those from the USA and by 22% (n=25) of those from 
Canada. Stockings were mostly used by delegates from France (42%, n=33), 
Scandinavia (38%, n=63) and the UK (35%, n=102). 
Use of preventive measures by risk groups
Individuals with a known risk factor for thrombosis more often used preventive 
measures (90%, n=280) than those without known risk factors (77%, n=1384). 
Pharmacological prophylaxis was used by 44% (n=130) of the individuals with a 
known risk factor for venous thrombosis and by 23% of the individuals without risk 
factors (n=379, difference 22%, CI95 16-28%). 27% (n=62) of the respondents 
with a risk factor used either LMWH or VKA during their flight, compared to 5% 
(n=61, difference 23%, CI95 17-29%) of those without a risk factor. LMWH was 
most frequently used by individuals with a history of venous thrombosis (33%, 
n=17) and known thrombophilia without a personal history of venous thrombosis 
(34%, n=21). VKA was used most by respondents with a positive history (16%, 
n=8). Aspirin was taken by 27% (n=79) of the individuals with a risk factor, 
compared to 19% (n=291) of those without a risk factor (difference 7%, CI95 2-
13%). Of the delegates with a risk factor, 37% (n=110) wore elastic compression 
stockings and of the individuals without a risk factor 14% (n=234) used stockings 
(difference 23%, CI95 17-29%). Stockings were most used by women who were 
pregnant or had given birth in the 3 months prior to the conference (79%, n=9). 
Use of preventive measures per class of travel
Delegates who travelled in business class used as much preventive measures 
(81%, n=399) as those in economy class (79%, n=1178). Only aspirin was used 
more by individuals in business class (27%, n=133) than by those in economy 
class (18%, n=274, difference 9% CI95  4-13%).
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- Medical doctor (786)
- Non-clinical scientist (706)

































































































































- Varicose veins (197)
- Recent surgery (16)
- Active Cancer (4)
- Estrogen use (204)
- Pregnancy /postpartum (15)
- Any risk factor (311)***























































* Walking around the airplane at least once every 2 hours or exercises as suggested in in-flight magazines or videos
** Walking, exercises, stockings, aspirin, LMWH or VKA
***  Personal history of venous thrombosis, known thrombophilia, varicose veins, recent surgery, active cancer, pregnancy or 
postpartum.
Multivariate analysis 
Several variables in this study were strongly linked. Medical doctors for example 
were older and more often male than individuals from other professions. They often 
travelled in business class and constituted a large part of the ISTH conference. 
Research fellows were the youngest and usually travelled economy class. They 
were more often female and more often attended the ISDB conference than 
individuals with other professions. The odds ratios from the logistic regression 
analysis, each adjusted for all other variables in the regression model, are 
shown in table 3. Odds ratios (OR) are shown for the use of all pharmacological 
prophylaxis (aspirin, LMWH and VKA) and the use of only LMWH or VKA. The 
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strongest independent determinants for the use of LMWH or VKA were presence 
of risk factors (OR for any risk factor vs none 6.1, CI95 3.8-9.6), professional 
background (OR for MDs vs other professional backgrounds 2.8, CI95 1.8-4.5), 
German nationality (OR vs Dutch 25.5, CI95 3.2-202.5) and Israelian nationality 
(OR vs Dutch 15.8, 95CI 1.5-169.7). There were no major differences for the use of 
pharmacological prophylaxis between sexes and class of travel.
Table 3:  Odds ratios for use of any anticoagulants (aspirin, LMWH or VKA) and for the use of only LMWH or VKA, per subgroup. Each 
variable was adjusted for the others by logistic regression analysis
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Ref: reference category. The odds ratio indicates the ratio between odds in the category of interest and the reference category
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In-flight behavior
In-flight behavior per subgroup is shown in Table 4. In-flight behavior also varied 
considerably per country. Almost 90% of all respondents took at least 3 non-
alcoholic beverages and almost half of the delegates (48%, n=978) took at least 
6 non-alcoholic consumptions. Overall, alcohol was consumed by 65% of all 
participants. Individuals from Scandinavia, Germany, the UK and the Netherlands 
consumed the highest number of alcoholic beverages. Sleeping medication was 
mainly used by the French (27%), Israeli (25%) and Americans (23%).
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Discussion
In this study amongst delegates of three international conferences in Australia, we 
showed that a considerable number used some kind of preventive measure for air 
travel-related thrombosis. Overall, 80% of the participants in this survey used one 
or more measures to prevent air travel-related thrombosis. The use of preventive 
measures varied between conference content, professional background, risk 
groups and nationality. 
 Delegates of the haemostasis and thrombosis conference used more 
aggressive preventive measures than delegates of the conferences that did 
not concern thrombosis. This is likely to be a consequence of greater concern 
about the association between air travel and thrombosis amongst professionals 
working in the field of thrombosis and haemostasis.
 Compared to people with other occupations, medical doctors more 
often used pharmacological prophylaxis (aspirin, LMWH and VKA). This may 
again reflect concern about a disease they are well-acquainted with, and also, 
particularly for LMWH and VKA, that they have more easy access to drugs. 
Still, it is of interest to note that medical doctors used more potentially harmful 
preventive measures than their non-clinical colleagues, while there is no evidence 
available that supports the use of LMWH or VKA, especially in individuals that 
have no known risk factors for venous thrombosis.  
 Individuals with known risk factors for venous thrombosis more often 
used preventive measures than those without risk factors. However, even some 
people who had no known risk factor for venous thrombosis used anticoagulant 
therapy (3% LMWH and 1% VKA) during their flight to Australia.
The large variation between countries may reflect cultural differences and 
possibly the effect of disparate views among medical opinion leaders.
Since we expected that many variables were linked this way, we performed 
a multivariate analysis. However, from this analysis it appeared that the 
determinants found in the univariate analysis were still all predictors for the use 
of preventive measures. The type of conference attended still was an important 
determinant, as well as professional background, the presence of risk factors 
and nationality. So the higher proportions of use of anticoagulants by delegates 
from the ISTH could not be explained by the higher number of medical doctors 
attending, but is probably indeed related to the greater concern about air travel-
related thrombosis in professionals working in this field.
 The limited guidelines on preventive measures for air travel-related 
venous thrombosis that are available generally promote drinking large amounts 
of non-alcoholic beverages and avoiding alcoholic consumptions. Only half 
of the respondents in this survey followed the advice regarding non-alcoholic 
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beverages, as 52% took less than 6 non-alcoholic consumptions, which is not 
much, considering that most respondents had been travelling for at least 20 
hours. Few people seemed worried about the dehydrating effect of alcohol, as 
more than half of the respondents consumed at least one alcoholic beverage and 
22% of all respondents consumed 3 or more alcoholic beverages. 
 One previous study investigated the use of preventive measures for 
air travel-related venous thrombosis amongst passengers arriving at Heathrow 
and Gatwick airport in the UK14. In that study, passengers with a personal 
history of thrombosis, a known ‘clotting tendency’, recent surgery and ongoing 
chemotherapy, as well as passengers on daily aspirin for other reasons were 
excluded. 18% of these passengers bought elastic compression stockings, 30% did 
exercises or moved around during their flight and 16% intended to take aspirin for 
prevention of flight-related thrombosis. If only inhabitants from the UK without the 
above mentioned risk factors were taken into account in our study, 295 respondents 
remained of whom 32% used aspirin, 65% did exercises and 35% used elastic 
compression stockings. The higher percentages in our study are likely to reflect the 
greater concern about the association between air travel and venous thrombosis 
among individuals who are employed in the field of thrombosis and haemostasis.
 A limitation of our study is that in the questionnaire, daily medication 
use could not be distinguished from occasional use for prophylaxis of air travel-
related thrombosis. In particular, in North-America daily aspirin use is quite 
common, as an observational study showed that 29% of the American citizens 
aged 34-64 used aspirin daily15. This may have contributed to the high prevalence 
of aspirin use in the USA and Canada and therefore it is not possible to say what 
proportion of the respondents in our study used aspirin only for prevention of 
air travel-related thrombosis. Another limitation in this study is the low response 
of 29% in delegates of the ISDB conference. Individuals who are concerned 
about thrombosis may have preferentially completed our survey, leading to an 
overestimate of the use of preventive measures. However, these limitations would 
not explain differences between subgroups.
 Convincing evidence on who is most at risk for developing thrombosis 
after air travel and which preventive measures would be most beneficial is not 
available at this time. In other circumstances, pharmacological prophylaxis 
is accepted in individuals at high risk, when there is a positive efficacy/safety 
ratio, such as in post-operative patients. However, as the risk for thrombosis 
decreases, this ratio decreases and the use of pharmacological prophylaxis 
becomes potentially unsafe. Large epidemiological studies are required to 
assess the absolute risk for developing symptomatic thrombosis after air travel 
and to identify individuals who are most at risk and who would therefore benefit 
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most from preventive measures. Furthermore, large randomized trials are 
necessary to assess which preventive measure is most beneficial, if at all, and to 
assess the optimal dose and duration of pharmacological prophylaxis.
 From this study we conclude that medical and non-medical preventive 
measures for air travel-related thrombosis are widely used and their use varies 
considerably between nationalities and professional backgrounds. The potential 
harm associated with anticoagulant prophylaxis stresses the need to gather 
evidence that should lead to clear guidelines.
Acknowledgements 
We would like to thank all delegates of the XXth ISTH Congress, the 15th ISDB 
Congress and the 13th Cochrane Colloquium for their kind participation in this 
study. Furthermore, we thank Professor Colin Chesterman, President of the XXth 
ISTH congress, Professor Richard Harvey, Chair of the 15th ISDB conference, 
Steve McDonald from the organizing committee of the 13th Cochrane Colloquium and 
Suzannah Hazell, Eventplanners Sydney, for their assistance in contacting the delegates. 
Use of preventive measures for air travel-related venous thrombosis in professionals who attend medical conferences52
Reference List
(1)   Arya R, Barnes JA, Hossain U, Patel RK, Cohen AT. Long-haul flights and deep vein thrombosis: 
a significant risk only when additional factors are also present. Br J Haematol 2002; 116:653-
654.
(2)   Cannegieter SC, Doggen CJM, van Houwelingen HC, Rosendaal FR. Travel-Related Venous 
Thrombosis: Results from a Large Population-Based Case Control Study (MEGA Study). PLoS 
Med 2006; 3.
(3)   Ferrari E, Chevallier T, Chapelier A, Baudouy M. Travel as a risk factor for venous thromboembolic 
disease: a case-control study. Chest 1999; 115:440-444.
(4)   Kelman CW, Kortt MA, Becker NG, Li Z, Mathews JD, Guest CS et al. Deep vein thrombosis and 
air travel: record linkage study. BMJ 2003; 327:1072.
(5)   Kraaijenhagen RA, Haverkamp D, Koopman MM, Prandoni P, Piovella F, Büller HR. Travel and 
risk of venous thrombosis. Lancet 2000; 356:1492-1493.
(6)   Samama MM. An epidemiologic study of risk factors for deep vein thrombosis in medical 
outpatients: the Sirius study. Arch Intern Med 2000; 160:3415-3420.
(7)   Lapostolle F, Surget V, Borron SW, Desmaizieres M, Sordelet D, Lapandry C et al. Severe 
pulmonary embolism associated with air travel. N Engl J Med 2001; 345:779-783.
(8)   Perez-Rodriguez E, Jimenez D, Diaz G, Perez-Walton I, Luque M, Guillen C et al. Incidence of 
air travel-related pulmonary embolism at the Madrid-Barajas airport. Arch Intern Med 2003; 
163:2766-2770.
(9)   Parkin L, Bell ML, Herbison GP, Paul C, Skegg DC. Air travel and fatal pulmonary embolism. 
Thromb Haemost 2006; 95:807-814.
(10)   Hughes RJ, Hopkins RJ, Hill S, Weatherall M, Van de WN, Nowitz M et al. Frequency of venous 
thromboembolism in low to moderate risk long distance air travellers: the New Zealand Air 
Traveller’s Thrombosis (NZATT) study. Lancet 2003; 362:2039-2044.
(11)   Schwarz T, Siegert G, Oettler W, Halbritter K, Beyer J, Frommhold R et al. Venous thrombosis 
after long-haul flights. Arch Intern Med 2003; 163:2759-2764.
(12)   Scurr JH, Machin SJ, Bailey-King S, Mackie IJ, McDonald S, Smith PD. Frequency and prevention 
of symptomless deep-vein thrombosis in long-haul flights: a randomised trial. Lancet 2001; 
357:1485-1489.
(13)   Kuipers S, Cannegieter SC, Middeldorp S, Robyn L, Büller HR, Rosendaal FR. The absolute 
risk of venous thrombosis after air travel: a cohort study of 8,755 employees of international 
organisations. PLoS Med 2007; 4:e290.
(14)   The extent of Aspirin Use for the Prophylaxis of DVT in Long Haul Flights. Ref type: internet 
communication. 2006.
(15)   Ajani UA, Ford ES, Greenland KJ, Giles WH, Mokdad AH. Aspirin use among U.S. adults 
behavioral risk factor surveillance system. Am J Prev Med 2006; 30:74-77.
53Use of preventive measures for air travel-related venous thrombosis in professionals who attend medical conferences

Chapter 4
The absolute risk of venous 
thrombosis after air travel: 
a study of 8 755 employees of 
international organisations
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Abstract
Background: The risk of venous thrombosis is approximately 2-4 fold increased 
after air travel, but the absolute risk is unknown. The objective of this study was to 
assess the absolute risk of venous thrombosis after air travel.
 Methodology and principle findings: We conducted a cohort study 
among employees of large international companies and organisations, who were 
followed between January 1st 2000 and December 31st 2005.  The occurrence of 
symptomatic venous thrombosis was linked to exposure to air travel, as assessed 
by travel-records provided by the companies and organisations. A long-haul flight 
was defined as a flight of at least 4 hours and subjects were considered exposed 
for a post-flight period of 8 weeks. A total of 8 755 employees were followed 
during a total follow-up time of 38 910 person-years. The total time employees 
were exposed to a long-haul flight was 6 872 person-years. In the follow-up 
period, 53 thromboses occurred, 22 of which within 8 weeks of a long-haul flight, 
yielding an incidence rate of 3.2/1000 person-years, as compared to 1.0/1000 
person-years in individuals not exposed to air travel (incidence rate ratio 3.2, CI95 
1.8-5.6). This was equivalent to a risk of 1 event per 4 656 long-haul flights. The 
risk increased with exposure to more flights within a short time frame and with 
increasing duration of flights. The incidence was highest in the first two weeks 
after travel and gradually decreased to baseline after 8 weeks. The risk was 
particularly high in employees under 30, women who used oral contraceptives, 
individuals who were particularly short, tall or overweight. 
 Conclusions/significance: The risk of symptomatic venous thrombosis 
after air travel is moderately increased on average, and rises with increasing 
exposure and in high-risk groups.
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Introduction
In 1951, Jacques Louvel reported four cases of venous thrombosis following air 
travel1. More recently, several investigators have shown an association between 
air travel and venous thrombosis, with a 2-4 fold increased risk in most studies2-
8 . Two follow-up studies demonstrated a dose-response relationship between 
the occurrence of pulmonary embolism shortly after arrival at the airport and 
the distance travelled9.10.  Still, the most relevant element, i.e. the absolute risk of 
symptomatic venous thrombosis after long distance air travel, remains unknown. 
One follow-up study demonstrated an absolute risk of severe pulmonary 
embolism occurring shortly after arrival of 1 per 200 000 passengers9, whereas 
another study showed a risk of fatal pulmonary embolism of 1.3 per million 
passengers11. Asymptomatic clots have been found in 1 to 10% of air travellers12-
14. Hence, the absolute risk of symptomatic venous thrombosis after long-haul 
travel must lie between these extremes.
 Knowledge of the absolute risk of symptomatic thrombosis after air 
travel is needed to provide travellers with solid advice regarding their actual risk 
and to evaluate the utility of prophylactic measures. Since there are two billion 
passengers annually15, even a small increase in risk will have a major impact on 
the number of events. Overestimation of the risk may lead to inappropriate use of 
potentially dangerous antithrombotic drugs16,17.
 In addition to estimating the absolute risk of symptomatic deep vein 
thrombosis or pulmonary embolism after long haul air travel, we assessed the 
effect of exposure to several flights within a short time frame, duration of travel 
and the occurrence of venous thrombosis in relation to the time passed after air 
travel. Finally, we determined the effect of air-travel within high-risk groups. 
Methods
Study design
We performed a cohort study among employees of large international companies 
and organisations. During the follow-up period, thrombotic events were linked to 
exposure to air travel. 
Participating companies and organisations
Participating companies and organisations were Nestlé (Vévey, Switzerland), 
General Mills (Minneapolis; Minnesota, USA), the Centers for Disease Control 
and Prevention (Atlanta; Georgia, USA), the World Bank and the International 
Monetary Fund (Washington; DC, USA), Shell Companies based in The Hague 
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(The Netherlands) and London (UK), Shell Exploration and Production (SIEP) 
based in Rijswijk (The Netherlands) and Sakhalin Energy Investment Company 
Ltd (SEIC) based in Sakhalin (Russia) and TNT NV (Thomas Nationwide 
Transport, Hoofddorp; the Netherlands). All organisations and companies had 
a central database with records of employees’ business travel. Start of follow-
up varied per company, between January 1st 1998 to January 1st 2001 or at 
start of the employment if later. Follow-up ended between December 1st 2002 
and January 1st 2006, when venous thrombosis was diagnosed or at the end of 
employment, whichever occurred first, with approximately 5 years of follow-up 
per company. 
Questionnaires and flight data
We developed web-based questionnaires, using Apian Survey Pro 3.0 (Seattle; 
Washington, USA). These contained questions about venous thrombosis occur-
rence (at any time point in the follow up period) and risk factors for venous throm-
bosis. Employees were invited to take part by a personal e-mail, containing a link 
to the questionnaire and a unique password, which ensured that each individual 
could enter only once. With intervals of a few weeks, non-responding employees 
received 2-3 reminders.  
 Date of travel and duration of travel (not including stop-over time) was tak-
en from the organisations’ travel database.
Outcomes
Participants who reported venous thrombosis were asked to fill in a consent form 
for medical chart review. Only symptomatic first venous thrombotic events that 
were diagnosed with objective methods were considered. Deep vein thrombosis 
had to be diagnosed by compression ultrasonography or venography. Pulmonary 
embolism had to be diagnosed by spiral-CT scanning, high probability 
ventilation-perfusion scanning or angiography. Superficial thrombophlebitis was 
not included. 
Statistical analysis
For the analysis of the overall effect of flying, exposure time was defined as 
a time-window of 8 weeks after a long haul flight (flights of at least 4 hours). 
For each individual, the total time exposed and not exposed was calculated. 
The incidence rate of venous thrombosis within 8 weeks of a long haul flight 
was calculated by dividing the number of cases that occurred in this exposure 
window by the number of exposed person-years. The incidence rate of venous 
thrombosis without exposure was calculated in the same way (events over 
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person-time outside exposure windows). The incidence rate ratio adjusted for 
age and sex was calculated using Poisson regression analysis. The overall 
effect of flying was assessed for the whole group of employees and separately 
for subgroups based on sex, age, oral contraceptive use, body mass index 
(BMI) and height., The number of person-years exposed and unexposed to oral 
contraceptive use was calculated for women younger than 50 years. 
 In addition, we calculated the absolute risk of venous thrombosis per 
flight, by dividing the number of cases that occurred within 8 weeks of a long haul 
flight by the total number of flights longer than 4 hours made by all responding 
employees.
 Employees were often exposed to more than one flight in the eight weeks 
exposure windows, so time-windows were frequently overlapping. To assess the 
effect of number of flights, the total time employees were exposed to 1 to 5 flights 
or more was calculated. Thus, incidence rates and rate ratios for exposure to 
1-2, 3-4 and 5 or more flights could be calculated (Figure 1a). Furthermore, we 
calculated the increase in risk for each extra flight using Poisson regression.
 To assess the effect of duration of travel, we calculated incidence rates 
and rate ratios within 8 weeks of flights of varying duration, i.e. 0-4 hours, 4-
8 hours, 8-12 hours, 12-16 and longer than 16 hours. If time windows were 
overlapping, only the duration of the longest flight was considered for this 
analysis (Figure 1b). The absolute risk per flight for each category of duration 
was calculated by dividing the number of cases that occurred within 8 weeks of 
a flight by the total number of flights in the corresponding category. Furthermore, 
we calculated the increase in risk for each extra hour of duration of a flight using 
Poisson regression. 
 The occurrence of venous thrombosis in relation to the period of time that 
had passed after travelling was assessed by calculating incidence rates and rate 
ratios for periods of 0-2, 2-4, 4-8 and 8-12 weeks after a flight of at least 4 hours. 
The period of 12 weeks after a flight was split into these 4 time windows, creating 
mutually exclusive exposure windows. If a person was exposed to several flights 
and hence to more than 1 time-window, the overlapping time was counted only in 
the time window closest to the flight (Figure 1c).
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Figure 1: Example of the calculation of person-years of exposure in 3 different ways.
An employee makes one flight of 6 hours on day 1 and another flight of 11 hours 
on day 10. 
a)  Per number of flights: from day 1 to 10, this employee is exposed to only 1 
flight. From day 10 to 56, he is exposed to 2 flights and from day 56 to 66 he is 
again exposed to 1 flight.
b)   Per category of duration: from day 1-10 the employee is exposed to one flight 
of 6 hours (so 10 days in the category of 4-8 hours). From day 10 to 56, he 
is exposed to 2 of which the longest is 11 hours (so 46 days in the category 
of 8-12 hours). From day 56 to 66 he is exposed to one flight of 11 hours (so 
again 10 days in the category of 8-12 hours).
c)   Per time window: from day 1 to 10, the employee is exposed to the time 
window of 0-2 weeks due to the first flight. At day 10, the time is ‘reset’, so from 
day 10 to 24, the employee is exposed to the time window of 0-2 weeks again. 
From day 24 to 38, he is exposed to the time window of 2-4 weeks, from day 
38 to 66 he is exposed to the time window of 4-8 weeks and finally, from day 
66 to 94 the time window is 8-12 weeks.
Results
A total of 27 496 employees were invited to participate. 8755 questionnaires were 
completed, yielding an overall response of 32% (range per organisation: 15-
80%). General characteristics of the study population are shown in Table 1. More 
than half of the responders (n=4915, 56%) were men and the mean age was 40 
years. The total follow-up time of participating employees was 38 910 person-
years, with a mean follow-up per participant of 4.4 years.
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Day 1, flight 1 
6 hours
Day 56 Day 84
Day 10, flight 2,
11 hours
Day 66 Day 94
a 1 flight 2 flights 1 flight
b 4-8 hours 8-12 hours 8-12 hours
b 0-2 wks 2-4 wks 8-12 wks0-2 wks 4-8 wks
Table 1: General characteristics of the study population and flight data
Characteristic
Age, mean (range) 39.9 (18-71)
Sex, % male 56
Oral contraceptive use (% in women <50) No OC use entire FU period
 OC use during part of the FU period










BMI: (n, %) < 25
 > 25 
4741 (54.7)
3934 (45.3)
Flight data: Total number of flights
 Flights 0-4 hours
 Flights 4-8 hours
 Flights 8-12 hours
 Flights 12-16 hours
 Flights >16 hours
 Median number of flights per year (range)
 Median number of flights > 4 hours per year (range)









3.9 hours (0-24 hours)
*BMI = body mass index in kg/m2
Flight data
Flight data are shown in Table 1. The 8 755 responders had made 315 762 
flights during follow-up, and 6440 individuals had travelled by air at least once. 
Approximately one third of all flights were long haul flights (at least 4 hours, 
n=100 208). The mean number of long haul flights per person per year was 2.6 
(range: 0-48, median: 3.5). 
Thrombotic events
Seventy-six employees reported that they had suffered from venous thrombosis 
in the follow-up period. Of these 76 possible cases 23 were not validated: 4 
employees did not give permission for medical chart review, 2 doctors could not 
be traced, 6 appeared to have suffered from an arterial event and 11 had been 
diagnosed with superficial thrombophlebitis. The remaining 53 employees all had 
an objectively confirmed venous thrombotic event. Deep vein thrombosis of the 
leg was diagnosed in 34, pulmonary embolism in nine, a combination in eight 
and deep vein thrombosis of the arm in two. 
Absolute risks and incidence rate ratios
The overall incidence rate of venous thrombosis was 1.4 per 1000 person-
years (95% confidence interval (CI95) 1.0-1.8/1000 person-years). The total time 
employees were exposed to a post-flight period of 8 weeks added up to 6872 
person-years when only flights longer than 4 hours were considered. Twenty-two 
events occurred within eight weeks of a long haul flight, yielding an incidence 
61The absolute risk of venous thrombosis after air travel: a study of 8 755 employees of international organisations
rate of 3.2 per 1000 person-years (CI95 2.0-4.7/1000 person-years). The time 
the employees were not exposed to any flight (long- or short haul) was 27 772 
person-years, during which 29 cases occurred, yielding an incidence rate of 1.0 
per 1000 person-years (CI95 0.7-1.5/1000 person-years). Thus, the incidence rate 
ratio (IRR) was 3.2 (CI95 1.8-5.6). The total number of long haul flights made by 
the employees was 102429, hence the absolute risk of venous thrombosis was 
21.5/100 000 flights, or 1 per 4656 flights. 
Table 2: Incidence rates, absolute risks and incidence rate ratios within 8 weeks of long haul flights, for the whole study population 
as well as stratified on sex, age category, oral contraceptive use, height and bmi.












































<30 Yrs (1 392)
30-50 Yrs (6017)











































































































































*  Travel: No=no exposure to air travel within 8 weeks, Yes=exposure to a flight of at least 4 hours
#  PY: Person-years 
**  IR: Incidence rate per 1000 person-years, CI95: CI95
##  IRR: Incidence rate ratio adjusted for age and sex
$:  Reference category  
$$:  Oral contraceptive use amongst women <50 years  
***  Risk per flight: risk per 100 000 flights
###:   number of flights needed to cause one case
Both the unexposed incidence rate and the incidence rate in the exposed were 
higher in women (1.3/1000 person-years and 4.4/1000 person-years) than in 
men (0.8/1000 person-years and 2.7/1000 person-years), so their rate ratios 
were approximately the same (Table 2). Although the unexposed incidence rate 
of venous thrombosis increased with age, the incidence rate in the subjects 
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exposed to air travel was highest in the youngest age category (4.9/1000 
person-years, CI95 0.9-12.1/1000 person-years) and lowest in the oldest 
(2.9/1000 person-years, CI95 0.7-6.5/1000 person-years), and hence the rate 
ratio decreased with age, with an IRR of 7.7 (CI95 1.6-38.4) for those under 30 
(Table 2). Women using oral contraceptives had an increased risk of venous 
thrombosis, both at baseline (IR 1.9, CI95 0.6-3.9) and after long distance flights 
(IR 6.6, CI95 1.2-16.4). Thus, the incidence rate ratio of exposure to air travel was 
higher in women using oral contraceptives (3.6, CI95 0.8-14.9) than in women 
not using hormone therapy (2.2, CI95 0.6-8.1). The baseline incidence rate of 
venous thrombosis did not differ much between subgroups based on height. 
The incidence rate after air travel was highest in individuals shorter than 165 cm 
(IR 6.3/1000 person years, CI95 2.4-12.0/1000 person years) and lowest in those 
between 165 and 185 cm (IR 2.4/1000 person years, CI95 1.2-4.0/1000 person 
years). In employees taller than 185 cm, the incidence rate after air travel was 
3.6/1000 person years (CI95 0.9-8.1/1000 person years). Hence, the rate ratio 
was highest in the shortest employees (IRR 9.8, CI95 3.1-30.9). BMI did not affect 
the baseline thrombosis risk, but the incidence rate after air travel was higher in 
employees with a BMI over 25 kg/m2 (IR 4.7/1000 person years, CI95 2.6-7.4/1000 
person years) as compared to those with a BMI lower than 25 kg/m2  (IR 1.9/1000 
person years, CI95 0.7-3.7/1000 person years).
 The risk of venous thrombosis increased with the number of flights per 
employee, as shown in Table 3. When someone was exposed to only one or two 
long haul flights, the incidence rate was 2.6 (CI95 1.4-3.2) per 1000 person-years, 
which tripled after exposure to 5 or more long haul flights. With each extra flight 
the employees were exposed to, the risk increased 1.4-fold (CI95 1.2-1.6).
Table 3:  Incidence rates and incidence rate ratios for exposure to an increasing number of flights. Only flights longer than 4 hours 
were taken into account. 





















$  The reference category for calculation of incidence rate ratios was no flight longer than 4 hours in the preceding 8 weeks.
*  PY= Person-years
**  Incidence rate per 1000 person-years and 95% CIs
#  Incidence rate ratio adjusted for age and sex and 95% CIs
The effect of duration of travel is shown in Table 4. The incidence rate increased 
from 0.5/1000 person-years (CI95 0-1.4/1000 person-years) when employees 
had travelled for less than 4 hours, to 5.9/1000 person-years (CI95 1.5-13.4/1000 
person-years) when they had travelled for more than 16 hours. For each extra 
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hour duration of the flight, the incidence rate ratio increased 1.1 fold (CI95 1.1-1.2). 
Expressed as risk per number of flights, the risk increased from 1/106 667 flights 
for flights shorter than 4 hours up to 1/1264 for flights longer than 16 hours.
Table 4: Incidence rates and incidence rate ratios after flights of increasing duration. 


















































$ The reference category for calculation of incidence rate ratios was no flight in a time-window of 8 weeks
* PY: Person-years
** IR: Incidence rate per 1000 person-years with CI95s
# IRR: Incidence rate ratio adjusted for age and sex with CI95s
*** Risk per flight: risk per 100 000 flights 
### Number of flights needed to cause one venous thrombosis\
In Table 5, the incidence rates and rate ratios are shown in relation to the time that 
had passed after travelling. In the first two weeks after a long haul flight, the risk 
of venous thrombosis was highest, with an incidence rate of 4.7 per 1000 person-
years (CI95 2.4-7.7/1000 person-years). The risk gradually decreased with time 
and returned to the baseline risk after 8 weeks. 
Table 5:  Incidence rates and incidence rate ratios in varying time windows after long haul flights. Only long haul flights (>4 hours) 
were taken into account
Time window Cases PY* IR (95%CI)** IRR (95%CI)#


























*  Person-years  
**  Incidence rate per 1000 person-years and CI95s
#  Incidence rate ratio adjusted for age and sex and CI95s
$  Reference category
Discussion 
In this follow-up study, we found an overall absolute risk of symptomatic venous 
thrombosis of 1 per 4656 passengers within 8 weeks after flights longer than 4 
hours. This is equivalent to an incidence rate of 3.2 per 1000 person-years. The 
risk was 3.2-fold increased compared to those who did not travel by air. The 
risk of venous thrombosis increased with exposure to several flights and longer 
duration of travel and it decreased with time after a flight. It was particularly high 
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in younger travellers, women - especially those taking oral contraceptives - 
individuals who were particularly short or tall and those with a BMI over 25 kg/m2, 
although due to the small number of cases, some confidence intervals were wide, 
indicating considerable uncertainty for the effect estimates.
 The observed rate ratio of 3.2 for flights longer than 4 hours is similar to 
the odds ratios found in most case-control studies3,4,7,8. Only two studies have 
previously described absolute risks of venous thrombosis after air travel, but only 
for severe pulmonary embolism occurring immediately after flying9,10. In our study, 
the risk of venous thrombosis was highest in the first 2 weeks after air travel, 
which was also demonstrated by Kelman in a record-linkage study5.
 Previous studies showed a dose-response relationship between the 
distance travelled and the risk of venous thrombosis9,10. In our study we observed 
three dose-response relationships. The risk of venous thrombosis increased 
with duration of air travel and number of flights and decreased with time after the 
flight. These dose-response relationships are in line with a causal association 
between air travel and deep vein thrombosis.
 The effect of air travel was pronounced in women using oral 
contraceptives. This was also demonstrated in a previous case-control study7. 
Travellers who were particularly short or tall also had a higher risk of venous 
thrombosis after air travel than those with a height between 165 and 185 cm. In 
the tall travellers, this may be explained by an extremely cramped position due 
to insufficient leg-space. In travellers who are shorter than 165 cm, the increased 
risk may be explained by pressure on the poplitial vein by the airplane seat, when 
their feet do not touch the floor. This higher risk in both tall and short travellers 
was previously found in a large population-based case-control study3. This is an 
important finding that has now been demonstrated in two different populations, 
indicating a need for adjustable seating in the aircraft. 
 A remarkable finding in our study was that the incidence rate of venous 
thrombosis after exposure to flights shorter than 4 hours seemed lower (0.5/1000 
person-years) than the unexposed incidence rate (1.0/1000 person-years). 
Although the confidence intervals overlap and a difference by chance cannot be 
ruled out, we think that it may be explained by a so-called healthy traveller effect, 
which has also been proposed by Kelman and colleagues5. This implies that the 
incidence rate in the absence of travel is lower in a travelling population than in 
the general population, since the former is generally healthier. To assess whether 
this was the case in our study, we separately calculated the baseline (unexposed) 
incidence rates for employees who travelled at least once a year and for those 
who travelled less than once a year. We found that the baseline incidence rate 
was indeed lower in employees who travelled more frequently (incidence rates 
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0.5/1000 person-years vs 1.2/1000 person-years for those who travelled hardly). 
One could therefore argue to use only employees who made at least one long 
haul flight per year as a reference group, which would have resulted in higher rate 
ratios (which can be inferred from the tables). However, the absolute risks would 
have remained the same.
 Another remarkable finding in this study was the high risk in young 
travellers. This may be due to a phenomenon called attrition of susceptibles, 
meaning that susceptible individuals are likely to develop a disease shortly 
after start of exposure to a risk factor, such as haemorrhage shortly after start 
of anticoagulant therapy18. Most employees in our cohort had been frequent 
travellers long before our observation period started. Since the youngest 
employees are most likely to be ‘new frequent travellers’, this may explain the 
high absolute risk of thrombosis after air travel in the youngest age category.  
We assessed whether this was the case as follows: If attrition of susceptibles is 
present, the baseline incidence rate (i.e. the incidence rate of venous thrombosis 
without exposure to air travel) in employees who hardly travel (less than once a 
year) would increase with age. The baseline incidence in employees who do fly 
frequently (> once a year) would not increase as much with age, since in this 
group, susceptible individuals would already have suffered from VT at a younger 
age, soon after they became frequent traveller, and hence be excluded from our 
study population. We found that in our study, the baseline incidence in individuals 
with a low travel-frequency (less than once a year) indeed rose from 0.7/1000 
person years in the youngest age category (<30 years), to 3.2/1000 person 
years in the oldest age category (>50 years). In contrast, in individuals with a 
higher travel frequency, the baseline incidence rate in both the youngest age 
category and those between 30 and 50 was 0.8 per 1000 person years, whereas 
no VT occurred in 1521 person-years in the oldest age category. Furthermore, 
in the individuals with a low travel-frequency (< once per year), the incidences 
in all age-groups were very high in case they did travel (24/1000 person years 
for those under 30, 7/1000 person years for those between 30-50 and 40/1000 
person years for those over 50). So, in these subjects, who do not travel on a 
regular basis, the thrombosis risk is high when they occasionally do. These 
results all suggest that the risk of air-travel related VT is highest in susceptible 
subjects soon after they first start travelling by air, i.e. that attrition of susceptibles 
is present. 
 A possible limitation of this study is the response of 32%. Employees 
who suffered from venous thrombosis may be more likely to complete the 
questionnaire than employees who did not. This would only create bias if 
employees who suffered from VT directly after air travel responded more 
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frequently than those who suffered from thrombosis without air travel. The 
response varied considerably per organisation between 15% and 80%. To assess 
the effect of the response, we analyzed organisations with a low response 
(<60%) and those with a high response (>60%) separately. The outcomes did 
not differ substantially between these two groups of employees, indicating that 
the low response did not bias our findings. Furthermore, we may have missed 
employees who died or stopped working due to disability resulting from a venous 
thrombosis. Although this is unlikely to have occurred often, it may have led to an 
underestimation of the number of cases.
 Another limitation is that these results cannot be generalized to an older, 
less healthy population. This study has been performed in a working population 
with a mean age of 40. We do not have any data on people older than 70, nor on 
individuals who are not fit enough to be employed. Considering this, the absolute 
risk of venous thrombosis in the general population is likely to be higher than the 
risk we found. Furthermore, the results cannot be generalized to individuals that 
have a history of venous thrombosis, as we only considered first events.
From this cohort study among employees of international organisations 
and companies, we conclude that the absolute risk of symptomatic venous 
thrombosis within 8 weeks of a flight of at least 4 hours is approximately 1 per 
4500 flights. Furthermore, we found 3 dose-response relationships: the risk of 
venous thrombosis increased with duration of travel and number of flights a 
person was exposed to and decreased with time after a long haul flight. The 
results of our study do not justify the use of potentially dangerous prophylaxis 
such as anticoagulant therapy for all long haul air travellers, since this may do 
more harm than good17. However, for some subgroups of people with a highly 
increased risk, the risk-benefit ratio may favour the use of prophylactic measures. 
Large randomized trials are required to assess who would benefit most from 
which prophylactic measure.
67The absolute risk of venous thrombosis after air travel: a study of 8 755 employees of international organisations
Reference List
(1)   Jacques-Louvel. [Four cases of phlebitis due to air travel.]. Arch Mal Coeur Vaiss 1951; 44:748-
749.
(2)   Arya R, Barnes JA, Hossain U, Patel RK, Cohen AT. Long-haul flights and deep vein thrombosis: a 
significant risk only when additional factors are also present. Br J Haematol 2002; 116:653-654.
(3)   Cannegieter SC, Doggen CJM, van Houwelingen HC, Rosendaal FR. Travel-Related Venous 
Thrombosis: Results from a Large Population-Based Case Control Study (MEGA Study). PLoS 
Med 2006; 3.
(4)   Ferrari E, Chevallier T, Chapelier A, Baudouy M. Travel as a risk factor for venous thromboem-
bolic disease: a case-control study. Chest 1999; 115:440-444.
(5)   Kelman CW, Kortt MA, Becker NG, Li Z, Mathews JD, Guest CS et al. Deep vein thrombosis and 
air travel: record linkage study. BMJ 2003; 327:1072.
(6)   Kraaijenhagen RA, Haverkamp D, Koopman MM, Prandoni P, Piovella F, Büller HR. Travel and 
risk of venous thrombosis. Lancet 2000; 356:1492-1493.
(7)   Martinelli I, Taioli E, Battaglioli T, Podda GM, Passamonti SM, Pedotti P et al. Risk of venous 
thromboembolism after air travel: interaction with thrombophilia and oral contraceptives. Arch 
Intern Med 2003; 163:2771-2774.
(8)   Samama MM. An epidemiologic study of risk factors for deep vein thrombosis in medical outpa-
tients: the Sirius study. Arch Intern Med 2000; 160:3415-3420.
(9)   Lapostolle F, Surget V, Borron SW, Desmaizieres M, Sordelet D, Lapandry C et al. Severe pul-
monary embolism associated with air travel. N Engl J Med 2001; 345:779-783.
(10)   Perez-Rodriguez E, Jimenez D, Diaz G, Perez-Walton I, Luque M, Guillen C et al. Incidence of 
air travel-related pulmonary embolism at the Madrid-Barajas airport. Arch Intern Med 2003; 
163:2766-2770.
(11)   Parkin L, Bell ML, Herbison GP, Paul C, Skegg DC. Air travel and fatal pulmonary embolism. 
Thromb Haemost 2006; 95:807-814.
(12)   Hughes RJ, Hopkins RJ, Hill S, Weatherall M, Van de WN, Nowitz M et al. Frequency of venous 
thromboembolism in low to moderate risk long distance air travellers: the New Zealand Air Trav-
eller’s Thrombosis (NZATT) study. Lancet 2003; 362:2039-2044.
(13)   Schwarz T, Siegert G, Oettler W, Halbritter K, Beyer J, Frommhold R et al. Venous thrombosis 
after long-haul flights. Arch Intern Med 2003; 163:2759-2764.
(14)   Scurr JH, Machin SJ, Bailey-King S, Mackie IJ, McDonald S, Smith PD. Frequency and preven-
tion of symptomless deep-vein thrombosis in long-haul flights: a randomised trial. Lancet 2001; 
357:1485-1489.
(15)   Annual Review of Civil Aviation 2005. ICAO Journal, the magazine of the International Civil Avia-
tion Organization 2006; 61:1-44.
(16)   Kuipers S, Cannegieter SC, Middeldorp S, Rosendaal FR, Büller HR. Use of preventive meas-
ures for air travel-related venous thrombosis in professionals who attend medical conferences. 
J Thromb Haemost 2006; 4:2373-6.
(17)   Rosendaal FR. Interventions to prevent venous thrombosis after air travel, are they necessary? 
No. J Thromb Haemost 2006; 4:2373-7.
(18)   Torn M, Algra A, Rosendaal FR. Oral anticoagulation for cerebral ischemia of arterial origin: high 
initial bleeding risk. Neurology 2001; 57:1993-1999.
68 The absolute risk of venous thrombosis after air travel: a study of 8 755 employees of international organisations
Chapter 5
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Abstract
Air travel increases the risk of venous thrombosis (VT), but not to an extent that 
necessitates the widespread use of prophylaxis. However, prophylaxis may be 
indicated in certain subgroups of travellers that are at increased risk. The aim of 
this study was to assess the effect of transient clinical risk factors for VT (such as 
recent surgery or pregnancy) on the risk of air travel-related VT.
 Methods: A nested case-control study in a cohort of employees of 
international companies and organisations. Through questionnaires we assessed 
the occurrence of VT and prevalence of its risk factors. Exposure to air travel 
was assessed using flight data provided by the companies. Odds ratios were 
calculated for each risk factor separately and for the combination of these risk 
factors with air travel. 
 Results: Transient risk factors that showed most interaction with air travel 
were surgery (OR of surgery combined with air travel 19.8 (CI95 5.6-70.1)), malignant 
diseases (OR 18.0, CI95 2.2-148.7) and pregnancy (OR 14.3, CI95 1.7-121.0).  
Conclusions: The risk of travel-related VT is highest in pregnant travellers, those 
who have recently undergone surgery and those with a malignant disease.
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Introduction
Since the first 4 cases of venous thrombosis related to air travel were published 
by Jacques Louvell in 19511, many authors have described case-reports of 
travel-related venous thrombosis. Only after a young woman died of pulmonary 
embolism at Heathrow Airport shortly after an intercontinental flight, more 
controlled studies on the association between long distance travel and venous 
thrombosis have been performed.
 First, case-control studies demonstrated that the risk of symptomatic 
venous thrombotic events within a few weeks after a long haul flight is 
approximately 2-4 fold increased 2-8. We recently described the same relative 
risk in a cohort-study among frequently travelling employees of international 
companies and organisations9. In this study, the absolute risk of developing 
symptomatic venous thrombosis within 8 weeks of flights longer than 4 hours was 
1 in 4500 flights. This risk increased with flight-duration and the number of flights 
a person was exposed to and decreased with time after a long haul flight. These 
three dose-response relationships strongly indicate a causal association between 
air travel and venous thrombosis. 
 The absolute risk of 1 in 4500 passengers in the general travelling 
population is not high enough to promote the widespread use of potentially 
harmful preventive measures, such as anticoagulant therapy. However, for 
some subgroups of travellers at highly increased risk, the risk-benefit ratio may 
favour the use of prophylactic measures. It is therefore important to identify 
individuals that are most at risk for developing travel-related venous thrombosis. 
In previous studies, the risk was found to be increased in individuals using oral 
contraceptives, in those who were particularly short, tall or obese and in travellers 
with factor V Leiden mutation3-7. The effect of other risk factors, such as recent 
surgery, pregnancy or a plaster cast, on the risk of venous thrombosis in air-
travellers has not been studied before. 
 The objective of the current nested case-control study among frequently 
flying employees of international companies and organisations was to assess the 
effect of transient classical risk factors for venous thrombosis on the occurrence 
of air travel-related venous thrombosis.
Methods
Study design
We performed a cohort study of frequently travelling employees of large 
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international companies and organisations. The occurrence of venous 
thrombosis was related to exposure to air travel. The design of the study has 
been described in detail in a previous publication9. To assess the effect  
of transient risk factors for VT, we performed a case-control analysis  
within this cohort. 
Data collection and questionnaires
The cohort in this study consisted of employees of large international companies 
and organisations in which air travel was frequent. The employees were followed 
for a period of approximately 5 years. Start of follow up varied per company, 
between January 1st 1998 to January 1st 2001 or at start of the employment if later. 
Follow-up ended at a fixed date per company, between December 1st 2002 and 
January 1st 2006, or when venous thrombosis was diagnosed or at the end of 
employment, whichever occurred first.
 All participating employees received a web-based questionnaire to 
assess the occurrence of venous thrombosis during the follow up period. 
Furthermore, we asked questions on presence of transient risk factors for venous 
thrombosis in a three-month period. Individuals who suffered from venous 
thrombosis were asked to answer these questions for the three months preceding 
their diagnosis. Individuals who had not suffered from venous thrombosis were 
asked to answer these questions for a randomly picked period of 3 months. 
Thus, we assessed the prevalence of surgery, plaster-cast, pregnancy, delivery, 
hormone replacement therapy and malignancies (active malignant disease) in the 
3-month period that we were interested in. We did not specify the type of surgery. 
Flight data (date and duration of each individual flight) were provided by the 
participating companies. Using these data, we assessed who had been exposed 
to at least one long haul flight (a flight of at least 4 hours duration) in the three 
month period that we were interested in.
 The first part of our study, performed in one company (Nestlé, Vevey, 
Switzerland), was  a pilot study. Employees from this company (n= 1163) had to 
be excluded from the current analysis, since the questions regarding transient 
risk factors for venous thrombosis were added after this pilot study. 
Outcomes
Participants who reported venous thrombosis were asked to sign a consent 
form for medical chart review. Only symptomatic first episodes of venous 
thrombosis, diagnosed with objective methods, were considered. Deep 
vein thrombosis had to be diagnosed by compression ultrasonography 
or venography. Pulmonary embolism had to be diagnosed by spiral-CT 
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scanning, high probability ventilation-perfusion scanning or angiography. 
Superficial thrombophlebitis was not included. 
Statistical analysis
To assess the effect of transient risk factors for venous thrombosis, we used 
a nested case-control design and determined odds ratios. We assessed how 
many employees were exposed to neither air travel nor the other risk factor (for 
example surgery), only air travel, only the other risk factor and both air travel and 
the other risk factor. Odds ratios and corresponding 95% confidence intervals 
were calculated for these exposure categories, with individuals exposed to 
neither air travel nor the other risk factor as a reference category. All odds ratios 
were adjusted for age and sex using logistic regression. 
For all statistical analyses we used SPSS version 12.0 (SPSS Inc., Chicago, Ill) 
and Stata statistical software (Stata Corp LP, College Station, TX).
Results
Participants and thrombotic events
A total of 8 755 employees of 8 different companies or organisations participated 
in our study. General characteristics of all participants have been described in a 
previous publication9. More than half of the responders (n=4915, 56%) were men 
and the mean age was 40 years. Of these 8 755 employees, 1 163 participated in 
the pilot study, and were excluded from the current analysis. The remaining 7 592 
employees were followed up for a total of 33 279 person years (py), with an average 
follow up per person of 4.4 years. The total time the employees were exposed to air 
travel added up to 5 916 py. In the follow up period, 44 employees were diagnosed 
with venous thrombosis. Twenty-seven were diagnosed with deep vein thrombosis 
of the leg, 8 with pulmonary embolism, 7 with both deep vein thrombosis of the leg 
and pulmonary embolism and 2 with deep vein thrombosis of the arm. Out of the 
44 thrombotic events, 18 occurred within 3 months of a long haul flight.
Effect of transient risk factors
To assess the effect of transient risk factors for VT, we asked questions about the 
presence of such risk factors in a three-month period: the three months before the 
diagnosis for the cases and a randomly picked three month period for the non-
cases. We calculated odds ratios for presence of only the risk factor, only air travel or 
both, as compared to employees who had not travelled by air without the risk factor 
of interest. All odds ratios were adjusted for age and sex and are shown in Table 1.
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As compared to non-travellers who had not recently undergone surgery, individuals 
who had undergone surgery had an odds ratio of 9.1 (CI95 3.6-23.1). For individuals 
who had travelled and undergone surgery it was 19.8 (CI95 5.6-70.1).
 For presence of a malignant disease (diagnosed in the follow-up period 
or within 5 years before start of the follow up period), the OR without air-travel 
was 8.8 (CI95 2.0-39.4). There was only one patient who suffered from cancer 
and had travelled by air in the three months before the diagnosis of VT (OR 18.0, 
CI95 2.2-148.7).
 Out of the 44 cases, 4 had had a plaster cast in the three months 
preceding their diagnosis, of which one had also travelled by air. The odds ratio 
for plaster cast only was 23.9 (CI95 6.7-85.9), whereas it was 24.4 (CI95 2.9-
207.1) for both plaster cast and air travel.
 For the analysis of the effect of oral contraceptives, hormone 
replacement therapy (HRT), pregnancy or delivery, only female cases and 
controls were included. There were 26 female cases, 10 of whom had taken oral 
contraceptives. The odds ratio for women only taking oral contraceptives was 
3.2 (CI95 1.0-9.7), whereas it was 8.2 (CI95 2.3-27.7) for women who took oral 
contraceptives and travelled by air. The odds ratio was 6.8 (CI95 1.5-32.8) for 
women who travelled and took HRT.
 Three women with thrombosis were pregnant in the 3 months before their 
diagnosis of VT. The odds ratio for both pregnancy and air travel was 14.3 (CI95 
1.7-121.0), whereas it was 4.3 (CI95 0.9-19.8) for women who had been pregnant 
but had not travelled.   
Discussion
In this nested case-control study in a cohort of frequently flying employees, we 
studied the effect of other risk factors for VT on the risk of VT after air-travel. Most 
of the transient risk factors we studied (recent surgery, plaster cast, malignant 
diseases, oral contraceptive use, pregnancy and recent delivery) also increased 
the risk of VT in our study population. For each of these risk factors, the risk was 
clearly higher in combination with air travel. This effect was strongest for recent 
surgery, malignant diseases and pregnancy.
 Interaction of air travel with transient risk factors for venous thrombosis 
(recent surgery, malignant diseases, plaster cast, oral contraceptive use, 
pregnancy and recent delivery) has not been studied extensively before. Two 
previous studies found a synergistically increased risk for the combination of oral 
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Table 1. Odds ratios for transient risk factors for venous thrombosis combined with air travel.

































































































































































* OR: Odds ratio, adjusted for age and sex  
contraceptive use and long distance travel3,7-9. In our population, the odds ratio 
of oral contraceptives without air travel was 3.2 (CI95 1.6-17.1), whereas it was 8.2 
(CI95 2.3-28.7) when air travel was present as well, confirming this synergistic 
effect between oral contraceptive use and long distance travel. This is also 
supported by a study in which women using oral contraceptives were found to 
have more coagulation activation during a long haul flight10.
 There is only one previous publication that mentioned the occurrence 
of venous thrombosis after air travel in post-surgical patients11, but it was not 
possible to assess the effect of combination of air travel and surgery on the 
risk of venous thrombosis in this study. In our study, the risk was already much 
increased in individuals with recent surgery (OR 9.1, CI95 3.6-23.1), but it was 
even higher in those who had also travelled by air (OR 19.8, CI95 5.6-70.1). 
 Similar odds ratios were found for the combination of malignant disease 
and recent air travel, although there was only one case with a malignancy who 
had also travelled by air in the 3 months preceding the diagnosis.  We observed 
no increased risk for the combination of air travel and plaster cast, but again, 
there was only one case who had a plaster cast and also travelled by air before 
the thrombotic event. 
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The effect of the combination of a recent delivery and air travel could not be 
assessed, since there were no women who had had venous thrombosis and 
both given birth and travelled by air in the 3 months before their diagnosis. Since 
air travel is usually discouraged in women over 32 weeks pregnant, it is likely 
that women about to give birth rarely travel by air. There was only one case who 
had travelled by air and been pregnant in the 3 months before the diagnosis. 
Therefore, the confidence interval of the odds ratio for the combination of the 2 
risk factors is wide (OR 14.3, CI95 1.7-121.0). 
 The same problem was encountered with hormone replacement therapy, 
since there were only relatively few women using HRT with only 3 cases, of whom 
2 had also travelled by air.
 A possible limitation of our study is the relatively small number of cases 
with a combination of air travel and the risk factor of interest. Therefore, the 
confidence intervals were wide. Nevertheless, we found consistently increased 
risks for almost all classical risk factors for venous thrombosis which appeared 
to double in combination with air travel. Furthermore, it may be possible that only 
the least sick employees who had a malignant disease or plaster cast travelled 
by air and that the sickest persons with these risk factors did not travel. This may 
have lead to an underestimation of the risk associated with these risk factors.  
 From this nested-case control study, we conclude that the risk of travel-
related venous thrombosis is most increased in travellers who have recently 
undergone surgery, those taking oral contraceptives and pregnant women. 
 The risk groups that we have identified in this study should be aware of their 
increased risk. In these populations, the risk-benefit ratio of prophylaxis may 
favour the use of prophylaxis. Therefore, large randomised controlled studies in 
travellers at increased risk are needed to assess which preventive measure is 
most effective and least harmful. 
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Chapter 6
The effect of elevated levels 
of coagulation factors on the 
risk of venous thrombosis 
in long distance travellers
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Abstract
The risk of venous thrombosis is increased after long distance travel. Identifying 
high-risk groups may provide a basis for targeted prevention. We assessed the 
effect of increased levels of coagulation factors and combinations of risk factors 
on the risk of venous thrombosis in travellers in a large case-control study. 
 We calculated odds ratios for 334 travellers (200 cases and 134 controls) 
with coagulation factors II (prothrombin, FII), VII (FVII), VIII (FVIII) and IX (FIX), 
fibrinogen and vWF above the 80th percentile, for increasing numbers of risk 
factors and for specific combinations of risk factors. The risk was increased in 
travellers with a high FII (OR 2.2, CI95 1.3-3.7) and FVIII (OR 6.2, CI95 3.6-10.5) 
as compared to travellers with normal levels. High FIX and fibrinogen levels 
increased the risk in air travellers (OR FIX 3.2, CI95 0.9-11.0; OR fibrinogen 2.0, 
CI95 0.7-5.5), but not in other travellers. The odds ratios increased with the 
number of risk factors and the risk was increased the most in women with the 
combination of oral contraceptives and high FVIII levels (OR 51.7, CI95 5.4-498). 
 From this case-control study in travellers, we conclude that increased 
levels of factors II and VIII increase the risk of venous thrombosis. Furthermore, 
the risk is greatly increased if other risk factors are present as well.
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Introduction
Several studies have shown an association between long distance travel and the 
risk of venous thrombosis. Most case-control1-6 and follow up studies showed 
a 2-4 fold increased risk7-9. A dose-response relationship between the distance 
travelled and the incidence of venous thrombosis has been demonstrated in 
three studies10-12 and the overall risk of venous thrombosis after air travel has 
been found to be 1 per 4500 flights in a frequently travelling population12.
 Even though the risk of venous thrombosis is increased after long 
distance travel, it is not sufficiently elevated to justify the use of prophylaxis 
in all long distance travellers, since most prophylactic measures, such as 
anticoagulant therapy, are potentially harmful13. Only in individuals at particularly 
increased risk the risk-benefit ratio may favour the use of such prophylactic 
measures. However, knowledge on who is most at risk among long distance 
travellers is limited. As a result, the use of prophylactic measures varies widel 14. 
Previous reports showed excess risks for travellers carrying the factor V Leiden 
mutation (FVL) or the prothrombin mutation (PT20210A), women using oral 
contraceptives and travellers who are obese or particularly tall or short5,6,12. The 
joint effect of long distance travel, either by air or by other modes of transport, 
and elevated levels of pro-coagulant factors has not been previously investigated
 The Multiple Environmental and Genetic Assessment of risk factors for 
venous thrombosis (MEGA) study is a large population-based case-control study 
aimed at assessing the combined effect of genetic and environmental risk factors 
for venous thrombosis. The aim of the current analysis was to assess the effect 
of elevated levels of coagulation factors and combinations with other known risk 
factors (FVL mutation, prothrombin mutation, increased body mass index, oral 
contraceptive use and a positive family history of venous thrombosis) on the risk 
of venous thrombosis in long distance travellers, both by air and by other means 
of transport.
Materials and methods
Patients and control subjects
The MEGA study is a population-based case-control study on genetic and 
environmental risk factors for venous thrombosis. Cases were consecutive 
patients with a first episode of deep vein thrombosis or pulmonary embolism 
recruited at six anticoagulant clinics in the Netherlands. Patients who were unable 
to complete a questionnaire (due to language or severe psychiatric problems) 
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and patients who died soon after the diagnosis were not included, nor were 
patients without a partner. Partners of patients were invited as control subjects. 
Patients and their control subjects were recruited between March 1st 1999 and 
August 31st 2004. Details have been described previously 6. From these patients 
and control subjects, we selected individuals who had travelled by air, bus, train 
or car in the 8 weeks prior to the index-date (date of the thrombotic event for each 
case-control pair). Each patient or control had made at least one journey of at 
least 4 hours. We used 4 hours and 8 weeks as cut off values for travel, because 
previous studies have found that the risk of venous thrombosis is increased in the 
first 8 weeks after journeys longer than 4 hours12. 
Questionnaire
All participants were asked to fill in a questionnaire, which contained questions 
regarding long distance travel by air, train, bus or car in the 8 weeks prior 
to the index date as well as questions on other (possible) risk factors for 
venous thrombosis, such as height, weight and oral contraceptive use. These 
questionnaires were sent to eligible patients and their partners shortly after the 
index date. 
Laboratory assays
Approximately three months after discontinuation of oral anticoagulant therapy, 
patients and their partners were invited for collection of a blood sample. In patients 
who were still on anticoagulant therapy one year after their event, blood was drawn 
during anticoagulant therapy. All assays were performed in an automated machine 
by laboratory technicians who were unaware of the case-control status of the 
samples. Plasma samples were available for 200 out of 233 cases and 134 out of 
181 control subjects. The remaining patients and control subjects either refused or 
were unable to visit the research centre for a blood draw. 
 Prothrombin activity (FII), Factor VII activity (FVII) and Factor VIII activity 
(FVIII) were measured with a mechanical clot detection method on a STA-R 
coagulation analyzer following the instructions of the manufacturer (Diagnostica 
Stago, Asnieres, France). Levels of factor IX antigen (FIX) were determined by 
enzyme-linked immunosorbent assay (ELISA). Fibrinogen activity was measured 
on the Sta-R analyzer according to methods of Clauss. In the presence of excess 
thrombin, the coagulation time of a diluted plasma sample was measured. Von 
Willebrand factor antigen (vWF) was measured with the immuno-turbidimetric 
method, using the STA liatest kit (rabbit anti-human vWF antibodies), following 
the instructions of the manufacturer. 
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Statistical analysis
The overall relative risk of travel in this study population has been previously 
described and was 2.1 (CI95 1.5-3.0)6. In the current analysis, we assessed the 
effect of elevated levels and activity of coagulation factors among travellers, as 
well as the effect of several combinations of risk factors. Hence, all relative risks 
are to be superimposed on the risk of travel itself when a comparison to non-
travellers is made.
 Odds ratios were adjusted for age and sex for elevated levels of all 
coagulation factors and their 95% confidence levels using logistic regression. 
Cut-off points were antigen or activity levels at the 80th and 90th percentile in the 
control population. Individuals who were using anticoagulant therapy at the time 
of blood collection were excluded from the analysis of the effect of vitamin K 
dependent coagulation factors (FII, FVII and FIX). Odds ratios were calculated 
separately for individuals who had travelled by air and those who had travelled by 
other means of transport. 
 In an effort to identify those at particularly high risk, we calculated risks 
for combinations of risk factors and determined the number of coagulation 
abnormalities present in each individual. Both high levels of coagulation 
factors that increased the risk of venous thrombosis in our population and well 
established prothrombotic risk factors15-17 were taken into account, i.e. FII, FVIII, 
FVL mutation and the prothrombin mutation (PT20210A mutation). Odds ratios 
were calculated for the presence of 1 and 2 or more prothrombotic factors, with 
travellers in whom all of these factors were absent as the reference category. The 
same analysis was performed including also environmental risk factors. For this 
analysis, only risk factors that have previously been described in the literature 
and that were sufficiently prevalent in our population to allow such analyses were 
considered6;18-20. These were a high body mass index (BMI in the third tertile as 
compared to the first, i.e. higher than 26.9 kg/m2 as compared to lower than 23.7 
kg/m2), oral contraceptive use and a positive family history for venous thrombosis 
(at least one thrombotic event in a parent, brother or sister).  
 For all analyses, one could discuss whether a conditional (‘matched’) 
analysis would be necessary, since partners of patients were used as a control 
population. As they were usually of the opposite sex, and generally in a similar 
age range, the controls were not a random sample of the population. Generally, 
whether or not this is relevant depends on the exposure in question. The 
exposure of interest here was the effect of coagulation abnormalities on travel-
related thrombosis in addition to the actual travel itself. There is no reason to 
assume that high levels of clotting factors are more common among partners of 
patients than in the general population and an unconditional analysis suffices.  
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Therefore we performed unconditional analyses and adjusted for the potential 
confounders age and sex. 
 For all statistical analyses we used SPSS version 12.0 (SPSS, Chicago, 
Ill, United States).
Results
Patients and control subjects
Of the 1906 consecutive patients with venous thrombosis, 233 had travelled by 
air, bus, train or car in the 8 weeks prior to their thrombotic event. Of the 1906 
control subjects, 182 had travelled before the index date. Plasma was available 
in 200 out of 233 patients (86%) and 134 of 182 control subjects (72%). Table 1 
shows the general characteristics of cases and controls. 
Table 1:  General characteristics of patients with venous thrombosis and control subjects who travelled by air and those who travelled 
by other modes of transportation. 
Characteristic Air travellers Other travellers




































*  BMI = body mass index, OC = oral contraceptives 
** Percentage of pre-menopausal women.
Coagulation factors
Mean FII, FVII, FVIII, FIX, fibrinogen and vWF levels are shown in table 2, as well 
as their cut-off levels for the 80th and 90th percentile in the control population. 
Odds ratios in travellers for elevated levels of these coagulation factors for 
both cut-off levels are shown in table 3. This table also shows the odds ratios 
separately for air travellers and other travellers, with the 80th percentile as cut-off 
level, all compared to travellers with normal levels.
Table 2:  Levels and activity of coagulation factors in patients with venous thrombosis and control subjects and cut-off values for the 
80th and 90th percentile in control subjects.
Coagulation factor Mean (range) Mean (range) P80 P90
Cases Controls Controls Controls
FII activity*, IU/ml 112 (65-150) 108 (75-150) 117 127
FVII activity, IU/ml 113 (58-250) 110 (47-170) 132 149
FVIII activity, IU/dl 140 (61-263) 106 (37-193) 130 144
FIX, IU/dl 106 (63-159) 105 (66-163) 118 128
Fibrinogen activity, g/l 3.3 (2.0-6.2) 3.2 (2.0-4.6) 3.6 3.9
vWF, g/l 147 (67-567) 109 (21-273) 134 154
*  Cases and controls that were using anticoagulant therapy at the time of the blood draw were excluded for calculation of means of 
vitamin-K dependent coagulation factors.
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High FII levels increased the risk of venous thrombosis among travellers. The 
odds ratio was similar for cut-off levels at the 80th (OR 2.2, CI95 1.3-3.7) and 90th 
percentile (OR 1.7, CI95 0.9-3.4). This association was somewhat stronger in air 
travellers (OR 3.0, CI95 1.2-7.7) than in other travellers (OR 1.9, CI95 1.0-3.7). 
Adjustment for presence of the PT20210A mutation did not affect our results.
High FVII levels did not show an association with venous thrombosis in travellers, 
neither when we used the 80th percentile (OR 1.1, CI95 0.7-2.0) nor the 90th 
percentile (OR 0.6, CI95 0.3-1.3). 
 High levels of FVIII had the most pronounced effect on the risk of venous 
thrombosis among travellers. The odds ratio was 6.2 (CI95 3.6-10.5) when the 
80th percentile was used and 7.5 (CI95 3.9-14.5) when the 90th percentile was 
used as cut-off level. After adjustment for vWF levels, the risk was attenuated but 
remained increased (OR 4.1, CI95 2.2-7.6 for FVIII above the 80th percentile). 
Neither FIX nor fibrinogen levels increased the risk of venous thrombosis when 
the 80th percentile was used. Using the 90th percentile, the odds ratio was 1.5 
(CI95 0.7-3.2) for high levels of FIX and 1.5 (CI95 0.8-3.1) for high fibrinogen 
levels. FIX levels above the 80th percentile increased the risk of venous 
thrombosis in air travellers (OR 3.2, CI95 0.9-11.0), but not in other travellers (OR 
0.9, CI95 0.5-1.7). For fibrinogen concentrations above the 80th percentile, we 
again found an effect in air travellers only (2.0 (CI95 0.7-5.5) vs 1.1 (CI95 0.6-2.0)).
 Elevated levels of vWF increased the risk of venous thrombosis (OR 4.6, 
CI95 2.7-7.7) for all travellers, with no major differences between air travellers and 
other travellers. However, the effect disappeared after adjusting for FVIII. 
 Adjustment for oral contraceptive use did not affect any of the odds 
ratios mentioned above. We also calculated odds ratios separately for pulmonary 
embolism and deep vein thrombosis of the leg. There were no major differences 
between these 2 groups, although most odds ratios were slightly higher in the 
DVT group than in the PE group. 
 To assess whether duration of travel affected our results, we also 
calculated odds ratios including only individuals who had made at least 1 journey 
longer than 8 hours in the 8 weeks prior to the event or index-date. Again, this did 
not affect any of the results.
85The effect of elevated levels of coagulation factors on the risk of venous thrombosis in long distance travellers
Table 3: Odds ratios for venous thrombosis for elevated coagulation factors in 334 travellers. 
Coagulation Factor P80$ P90$$ P80air** P80other**
OR* (CI95) OR* (CI95) OR* (CI95) OR* (CI95)
FII 2.2 (1.3-3.7) 1.7 (0.9-3.4) 3.0 (1.2-7.7) 1.9 (1.0-3.7)
FVII 1.1 (0.7-2.0) 0.6 (0.3-1.3) 1.3 (0.5-3.3) 1.2 (0.6-2.3)
FVIII 6.2 (3.6-10.5) 7.5 (3.9-14.5) 5.4 (2.3-13.0) 6.9 (3.4-13.8)
FIX 1.2 (0.7-2.1) 1.5 (0.7-3.2) 3.2 (0.9-11.0) 0.9 (0.5-1.7)
Fibrinogen 1.3 (0.8-2.2) 1.5 (0.8-3.1) 2.0 (0.7-5.5) 1.1 (0.6-2.0)
vWF 4.6 (2.7-7.7) 5.0 (2.6-9.3) 4.1 (1.7-9.9) 4.9 (2.5-9.5)
* Odds ratios are adjusted for age and sex
**  Air= Odds ratios for individuals who had travelled by air. Other= Odds ratios for individuals who had travelled by bus, train or 
car
$:  Odds ratios elevated levels of all coagulation factors with the P80 in the control population used as cut off levels (cut off levels 
are mentioned in Table 1)
$$:  Odds ratio for elevated levels of all coagulation factors using the P90 in the control population as cut off levels (again, cut off 
levels are mentioned in Table 1)
Combinations of risk factors
Odds ratios for the number of coagulation abnormalities present per individual 
(FII, FVIII, FVL mutation and prothrombin mutation) are shown in Table 4. When 
one abnormality was present, the odds ratio was 4.3 (CI95 2.6-7.2) as compared 
to travellers in whom all factors were normal. This increased to an odds ratio 
of 10.0 (CI95 4.7-217) when 2 or more clotting abnormalities were present. The 
increase in odds ratios was more pronounced in air travellers than in other 
travellers.
Table 4: Odds ratios for venous thrombosis (adjusted for age and sex) for total number of risk factors present per individual. 
Cases Control All Air travellers Other travellers
n n OR (CI95) OR (CI95) OR (CI95)
Number of laboratory risk factors*
0 45 82 1# 1# 1#
1 99 42 4.3 (2.6-7.2) 3.1 (1.4-7.1) 5.4 (2.7-10.8)
≥ 2 56 10 10.0 (4.7-21.7) 36.4 (4.4-298) 7.3 (3.0-17.6)
Total number of risk factors**
0 12 48 1# 1# 1#
1 54 48 4.4 (2.1-9.2) 2.9 (0.9-9.6) 5.8 (2.2-15.4)
2 54 28 7.4 (3.4-16.3) 7.5 (2.2-25.9) 8.0 (2.9-22.4)
3 60 7 32.1 (11.7-88.2) - 22.9 (7.2-73.3)
4-7 20 3 23.9 (6.0-95.0) - 16.8 (3.7-77.1)
* High (>P80) FII, FVIII, FVL mutation and/or prothrombin mutation 
**  Any of the prothrombotic factors mentioned above, as well as oral contraceptives,  positive family history (at least 1 thrombotic event 
in a parent, brother or sister) and BMI (3rd tertile as compared to 1st ). The cut off values for tertiles of BMI were 23.7 and 26.9.
#  Reference category, travelling individuals in whom all coagulation factors are normal and in whom the clinical factors were absent
The odds ratio also increased with the total number of risk factors (coagulation 
abnormalities and environmental risk factors combined) present per subject. 
When only one out of 7 possible risk factors (FII, FVIII, FVL mutation, prothrombin 
mutation, a high BMI, oral contraceptive use and a positive family history) was 
present, the odds ratio was 4.4 (CI95 2.1-9.2) as compared to travellers with none. 
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This increased to 23.9 (CI95 6.0-95.0) when a traveller had 4 or more risk factors. 
The risk again increased slightly more in air travellers than in other travellers.
 Odds ratios for all combinations of risk factors are shown in Table 5. The 
risk was high for most combinations with FVL. Individuals with FVL combined 
with high FII had an odds ratio of 17.5 (CI95 2.3-135), combined with FVIII it was 
24.7 (CI95 4.4-139) and combined with a high BMI it was 20.5 (CI95 2.5-170).  
 Women using oral contraceptives who also had FVL had an odds ratio 
of 18.3 (CI95 2.0-171). Having a positive family history did not add to the risk of 
FVL alone (OR 4.7, CI95 1.7-16.5). Women using oral contraceptives with a high 
FVIII had an odds ratio of 51.7 (CI95 5.4-498) and in those with a high body mass 
index the risk was 31.4 fold increased (CI95 3.0-334) as compared to women 
who did not use oral contraceptives with a low body mass index. In women using 
oral contraceptives, having a positive family history doubled the risk (OR of the 
combination 10.7, CI95 1.5-75.6). The number of cases and control subjects with 
specific combinations was too small to calculate odds ratios for air travellers and 
travellers by other means of transport separately. 
Table 5 Odds ratios for venous thrombosis for combinations of risk factors. 
FII FVIII FVL* OC* BMI* Fam**
FII 2.2 (1.3-3.7)
FVIII 7.9 (3.4-18.3) 6.2 (3.6-10.5)
FVL 17.5 (2.3-135) 24.7 (4.4-139) 4.5 (1.9-10.4)
OC 4.6 (1.1-19.8) 51.7 (5.4-498) 18.3 (2.0-171) 5.0 (2.1-12.1)
BMI 9.5 (3.6-25.1) 18.6 (7.0-49.9) 20.5 (2.5-170) 31.4 (3.0-334) 1.9 (1.4-2.7)
Fam** 2.4 (0.9-6.1) 8.7 (3.5-21.7) 4.7 (1.7-16.5) 10.7 (1.5-75.6) 2.4 (1.0-5.8) 1.7 (1.0-2.9)
*  FVL = factor V Leiden mutation, OC= Oral Contraceptive use, BMI= body mass index > 26.9 kg/m2 as compared to a BMI of <23.7 
kg/m2 . For each combination, the odds ratio for presence of both risk factors compared to absence of both factors is presented. In the 
boxes where the risk factor in the column is the same as in the row, the odds ratio for presence of only that risk factor is given. 
Fam: a positive family history, meaning at least one thrombotic event in a brother, sister or parent
Discussion
In this case-control study amongst 334 long distance travellers, we demonstrated 
an increased risk of venous thrombosis in individuals with high levels of 
coagulation factors II and VIII. The relative risk increased with the number of 
coagulation abnormalities (factor II, VIII, prothrombin mutation and factor V 
Leiden mutation) and with the overall number of risk factors present per individual 
(coagulation factors, high body mass index, a positive family history and oral 
contraceptive use). The relative risk was highest in female travellers using oral 
contraceptives who also had high levels of FVIII (odds ratio 51.7, CI95 5.4-
498). Combinations with the factor V Leiden mutation were associated with a 
particularly high relative risk as well. All these effects were superimposed on the 
relative risk of travel itself, which is about two in this population6.
87The effect of elevated levels of coagulation factors on the risk of venous thrombosis in long distance travellers
Previous studies have also demonstrated a synergistic effect between long 
distance travel and other risk factors for venous thrombosis. Individuals with 
obesity, thrombophilia (factor V Leiden or the prothrombin 20210A mutation) 
and women taking oral contraceptives were shown to have an additionally 
increased risk when they travelled long distances 5,6. The effect of increased 
levels of coagulation factors and of combinations of other risk factors for venous 
thrombosis has not been studied in a travelling population before. In the general 
population, FVIII levels higher than 150% are associated with an approximately 
5-fold increased risk of venous thrombosis 16,17 and high FII increases the risk 
approximately two-fold 18. We observed similar odds ratios in our travelling 
population. However, levels of fibrinogen and FIX are also known to increase the 
risk of venous thrombosis 16,19 in the general population, while in our travelling 
population these factors were only associated with a mildly increased risk in 
individuals who travelled by air. 
 
For most coagulation abnormalities and their joint effect with environmental risk 
factors we observed a more pronounced excess risk for travellers by air than for 
travellers by other modes of transport. This may be explained either by a difference 
in baseline thrombosis-risk or by a different underlying mechanism (air travel 
compared to other modes of transport). In general, individuals who travel by 
air may have a lower baseline risk, because they have less other risk factors for 
venous thrombosis, such as malignant disease or severe obesity. This would lead 
to higher relative risks in those who travel by air, when the absolute excess risk 
due to an increased coagulation factor is equal for both modes of travel. However, 
when the baseline risk is similar in all travellers, a higher odds ratio for high levels of 
coagulation factors after air travel than after travel by other means, would indicate 
a different underlying pathophysiology. In our population, there were no major 
differences in baseline characteristics between those who travelled by air and 
those who travelled by other modes of transportation (Table 1). This indicates that 
the mechanism of venous thrombosis related to air travel may be different from that 
related to other modes of travel. In a previous study, coagulation parameters were 
measured both after air travel and after immobilisation only. Only after air travel, 
hypercoagulability was observed in a small subgroup of the participants, indicating 
that not only immobilisation plays a role in the pathogenesis of air-travel related 
venous thrombosis20. However, the numbers in our study were too small to draw 
solid conclusions regarding the difference between thrombosis after air-travel and 
that after travel by other means. 
A limitation of this study is that the blood sample was collected after the 
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thrombotic event. Therefore, we cannot exclude the possibility that differences 
in plasma levels of the coagulation factors between cases and control subjects 
were the result of the thrombotic event itself. However, the blood draw was 
performed at least 3 months after the thrombotic event and it is unlikely that 
the thrombotic event itself caused persistent abnormalities in coagulation 
factor levels. Furthermore, in a previous case-control study, no differences in 
coagulation factors were observed between patients in whom blood was drawn 
shortly after their thrombotic event as compared to those in whom the blood 
draw took place much later, sometimes even years after their diagnosis16,19. 
Anticoagulant therapy did not affect our results, since individuals who were 
still on anticoagulant therapy were excluded from analyses in which vitamin-K 
dependent coagulation factors were involved.
 Another limitation is that we did not have plasma samples available of 
14% of the cases and 26% of the control subjects. The reason for unavailability 
of a plasma sample may have been different in cases and control subjects. In 
cases, a reason for not visiting the research unit for a blood draw may have 
been severe illness, whereas in control subjects lack of motivation to visit the 
research centre for a blood draw may have been a reason for unavailability of 
a plasma sample. Cases who did not show up for a blood draw had more often 
suffered from pulmonary embolism than those in whom plasma was available, 
indicating that the former may have been more disabled after the thrombotic 
event. This would only have led to an underestimation of the effect of increased 
coagulation levels if pulmonary embolism is associated with higher levels of 
coagulation factors than other thrombotic events, which is unlikely. Only few 
studies have investigated this and the results are contradictory 21,22. Furthermore, 
as we analyzed data in long distance travellers only, we do not expect that severe 
illness, such as advanced cancer, was a cause of unavailability of a plasma 
sample, as long distance travel requires some degree of healthiness.
One of the reasons for performing this study was to find out whether risk groups 
can be identified that could be specifically targeted for prevention. We therefore 
questioned whether the risk of venous thrombosis in individuals with any of 
the risk factors we studied would be high enough for cost-effective screening 
in all travellers. The absolute risk of venous thrombosis is estimated as 1 in 
4500 flights of more than 4 hours 12. This is the risk in the general travelling 
population, including individuals with and without the risk factors that could be 
screened for. The prevalence of increased FII, FVIII or FIX is 20% (as we used 
the 80th percentile in the control population as cut-off level), that of the FVL 
mutation is approximately 5% and of the prothrombin mutation 2% 23,24. The 
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proportion of individuals with at least one of these risk factors in the general 
population is therefore 0.52 (1-0.8*0.8*0.8*0.95*0.98). In our study, the odds 
ratio for travellers with one or more of these risk factors, as compared to those 
with none, was 4.7. When 4500 travellers make a flight longer than 4 hours, one 
develops VT. Of these 4500 travellers, 2355 (52%) have at least one of the risk 
factors. Of the cases, 83.6% has at least one risk factor (cases are 4.7*52/48 
times more likely to have at least one risk factor than to have none). If a ‘positive 
test’ would lead to treatment with for example low molecular weight heparin 
(LMWH), which can prevent approximately 70% of the cases 25, 57.5% of the 
cases (70% of 82%) would be prevented. So to prevent one case of venous 
thrombosis, 7826 travellers need to be screened (4500 travellers to prevent 
0.575 thrombosis), of whom 4096 (52% of 7826) would have to be treated with 
LMWH. The risk of a major haemorrhage for the use of LMWH is approximately 
0.4% over a 14-day period 26, which is 0.09% per 3 days (assuming that each 
traveller would take LMWH for 3 days per journey). These numbers are derived 
from studies including only acutely ill patients. The bleeding risk in healthy 
travellers is probably much lower. If we would assume that the bleeding risk in 
healthy travellers is approximately 1/4th of that in acutely ill patients, 3 days of 
anticoagulation therapy would lead to 1 serious bleeding complication per 4667 
travellers, meaning that prevention of 1 thrombotic event would cause almost 1 
serious bleeding complication. This strategy can therefore not be recommended, 
being costly and with an unfavourable risk-benefit ratio. However, if screening 
and subsequent treatment with LMWH would be restricted to for example women 
using oral contraceptives, prevention of one event would require screening of 
534 travellers using oral contraceptives, of whom 255 would have to be treated. 
Targeted screening and prophylaxis may therefore be justifiable. Similarly, it 
may be considered to treat everyone with a substantially increased relative risk 
without screening, such as women with the combination of a high BMI and oral 
contraceptive use. These issues need to be further explored in a randomized 
controlled trial.
From this case-control study, we conclude that high levels of FII and FVIII 
increase the risk of venous thrombosis in travellers and that the risk is further 
increased with the number of risk factors present per individual, as well as 
in travellers with specific combinations of risk factors. The effect of the risk 
factors we studied is not strong enough to promote screening and subsequent 
potentially harmful prophylaxis in all long distance travellers. However, targeted 
screening and prophylaxis may be justifiable. 
The effect of elevated levels of coagulation factors on the risk of venous thrombosis in long distance travellers90
Reference List
(1)   Ferrari E, Chevallier T, Chapelier A, Baudouy M. Travel as a risk factor for venous thromboem-
bolic disease: a case-control study. Chest 1999; 115:440-444.
(2)   Kraaijenhagen RA, Haverkamp D, Koopman MM et al. Travel and risk of venous thrombosis. 
Lancet 2000; 356:1492-1493.
(3)   Samama MM. An epidemiologic study of risk factors for deep vein thrombosis in medical outpa-
tients: the Sirius study. Arch Intern Med 2000; 160:3415-3420.
(4)   Arya R, Barnes JA, Hossain U, Patel RK, Cohen AT. Long-haul flights and deep vein thrombosis: 
a significant risk only when additional factors are also present. Br J Haematol 2002; 116:653-
654.
(5)   Martinelli I, Taioli E, Battaglioli T et al. Risk of venous thromboembolism after air travel: interac-
tion with thrombophilia and oral contraceptives. Arch Intern Med 2003; 163:2771-2774.
(6)   Cannegieter SC, Doggen CJM, van Houwelingen HC, Rosendaal FR. Travel-Related Venous 
Thrombosis: Results from a Large Population-Based Case Control Study (MEGA Study). PLoS 
Med 2006; 3.
(7)   Hughes RJ, Hopkins RJ, Hill S et al. Frequency of venous thromboembolism in low to moder-
ate risk long distance air travellers: the New Zealand Air Traveller’s Thrombosis (NZATT) study. 
Lancet 2003; 362:2039-2044.
(8)   Schwarz T, Siegert G, Oettler W et al. Venous thrombosis after long-haul flights. Arch Intern Med 
2003; 163:2759-2764.
(9)   Kelman CW, Kortt MA, Becker NG et al. Deep vein thrombosis and air travel: record linkage 
study. BMJ 2003; 327:1072.
(10)   Lapostolle F, Catineau J, Lapandry C, Adnet F. Venous thromboembolism in long-distance air 
travellers. Lancet 2004; 363:896-897.
(11)   Perez-Rodriguez E, Jimenez D, Diaz G et al. Incidence of air travel-related pulmonary embolism 
at the Madrid-Barajas airport. Arch Intern Med 2003; 163:2766-2770.
(12)   Kuipers S, Cannegieter SC, Middeldorp S et al. The absolute risk of venous thrombosis after air 
travel: a cohort study of 8,755 employees of international organisations. PLoS Med 2007; 4:e290.
(13)   Rosendaal FR. Interventions to prevent venous thrombosis after air travel, are they necessary? 
No. J Thromb Haemost 2006; 4:2306-7.
(14)   Kuipers S, Cannegieter SC, Middeldorp S, Rosendaal FR, Büller HR. Use of preventive meas-
ures for air travel-related venous thrombosis in professionals who attend medical conferences. 
J Thromb Haemost 2006; 4:2373-6.
(15)   Pomp ER, Le Cessie S, Rosendaal FR, Doggen CJM. Risk of venous thrombosis: obesity and 
its joint effect with oral contraceptive use and prothrombotic mutations. Br J Haematol 2007; 
139:289-296.
(16)   Koster T, Blann AD, Briet E, Vandenbroucke JP, Rosendaal FR. Role of clotting factor VIII in effect 
of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 1995; 345:152-155.
(17)   Tsai AW, Cushman M, Rosamond WD et al. Coagulation factors, inflammation markers, and 
venous thromboembolism: the longitudinal investigation of thromboembolism etiology (LITE). 
Am J Med 2002; 113:636-642.
(18)   Chinthammitr Y, Vos HL, Rosendaal FR, Doggen CJM. The association of prothrombin A19911G 
polymorphism with plasma prothrombin activity and venous thrombosis: results of the MEGA 
study, a large population-based case-control study. J Thromb Haemost 2006; 4:2587-2592.
(19)   van Hylckama Vlieg A, Van der Linden I, Bertina RM, Rosendaal FR. High levels of factor IX 
increase the risk of venous thrombosis. Blood 2000; 95:3678-3682.
91The effect of elevated levels of coagulation factors on the risk of venous thrombosis in long distance travellers
(20)   Schreijer AJM, Cannegieter SC, Meijers JCM et al. Activation of coagulation system during air 
travel: a crossover study. Lancet 2006; 367:832-838.
(21)   Erkekol FO, Ulu A, Numanoglu N, Akar N. High plasma levels of factor VIII: an important risk 
factor for isolated pulmonary embolism. Respirology 2006; 11:70-74.
(22)   Bombeli T, de Conno E, Jutzi M, Fehr J. In patients symptomatic for deep-vein thrombosis factor 
VIII elevation is found twice as frequent as in patients symptomatic for pulmonary embolism. 
Thromb Haemost 2003; 89:198-200.
(23)   Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet 1995; 346:1133-1134.
(24)   Rosendaal FR, Vos HL, Poort SL, Bertina RM. Prothrombin 20210A variant and age at thrombo-
sis. Thromb Haemost 1998; 79:444.
(25)   Geerts WH, Pineo GF, Heit JA et al. Prevention of venous thromboembolism: the Seventh ACCP 
Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126:338S-400S.
(26)   Leizorovicz A, Cohen AT, Turpie AG et al. Randomized, placebo-controlled trial of dalteparin 
for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 2004; 
110:874-879.
The effect of elevated levels of coagulation factors on the risk of venous thrombosis in long distance travellers92
93X
Chapter 7
The incidence of venous 
thrombosis in commercial 
airline pilots: a cohort study 
of 2630 pilots
S.Kuipers , S.C.Cannegieter, M. van Haften, F.R.Rosendaal
Submitted for publication
Abstract
Airline pilots may be at increased risk of venous thrombosis because air travel has 
recently been established as a risk factor for venous thrombosis. The aim of this 
study was to assess the risk of venous thrombosis in a cohort of Dutch airline pilots. 
 Methods: Airline pilots who had been active members of the Dutch 
Airline Pilots Association (ALPA), in Dutch called the Vereniging Nederlandse 
Verkeersvliegers (VNV), were questioned for the occurrence of venous 
thrombosis, presence of risk factors for venous thrombosis and number of flight 
hours per year and rank. Incidence rates among pilots were compared to that of 
the general Dutch population and to a population of frequently flying employees 
of multinational companies. 
 Results: 2630 male pilots were followed up for a total of 20 420 person-
years. Six venous thromboses were reported, yielding an incidence rate of 
0.3/1000 py. The standardized morbidity ratio, comparing these pilots to the 
general Dutch population adjusted for age, was 0.8. Compared to the employees, 
this standardized morbidity ratio was 0.7 when all employees were included and 
0.6 when only the frequently travelling employees were included. The incidence 
rate did not increase with number of flight hours per year and did not clearly vary 
by rank. 
 Conclusions: the risk of venous thrombosis is not increased amongst  
airline pilots.  
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Introduction
Commercial airline pilots are occupationally exposed to factors that may have 
a negative impact on their health. Even though their overall mortality is lower 
than that in the general population1-3, some diseases occur more often in airline 
pilots. Cohort studies have shown that the incidence rate of malignant diseases is 
increased in aviation crew members3-11. Especially skin-cancer (both melanoma 
and non-melanoma), leukaemia and breast-cancer occur more frequently in 
airline cabin crew than in the general population, possibly due to exposure 
to cosmic radiation, jet fuel, cabin air pollutants or constant changing of the 
circadian rhythm. Cosmic radiation may also be responsible for an increased 
risk of developing cataract later in life12. Furthermore, the incidence rates of HIV 
and AIDS, dermatitis and injuries have been shown to be increased in cabin crew 
members3,13,14 as compared to the general population. 
 In recent years, it has become clear that long distance air travel 
increases the risk of venous thrombosis. Case-control and follow up studies 
have demonstrated that risk of venous thrombosis shortly after long haul travel is 
approximately 2-4 fold increased15-19. The absolute risk of a symptomatic venous 
thrombotic event within 8 weeks of flights longer than 4 hours is approximately 
1 in 4500 flights17. The risk increases with duration of travel17,20,21 and particularly 
when individuals are exposed to several flights within a short time period17. 
 Because of their frequent exposure to air travel and because of the 
higher prevalence of conditions that increase the risk of venous thrombosis 
(malignant diseases, injuries), commercial airline pilots may be at increased 
risk of developing venous thrombosis. No large epidemiological studies have 
so far investigated the incidence of venous thrombotic disease in airline pilots. 
Knowledge of this incidence rate is needed to provide airline pilots with solid 
advice regarding the use of prophylactic measures such as exercises or elastic 
compression stockings. When the incidence rate is indeed increased, venous 
thrombosis may be a serious occupational health problem for airline pilots, since 
they are usually not allowed to fly while using anticoagulant drugs.
 The aim of the current study was to assess the incidence rate of symptomatic 
venous thrombosis in commercial airline pilots and to compare this incidence rate to 
that of the general population as well as to that of a frequently travelling population of 
employees of international companies and organisations. The employees were used 
as a second control population in order to take the so-called healthy worker effect 
into account (meaning that the incidence rate of many diseases is lower in a working 
population than in the general population). Furthermore, we assessed the effect of 
number of flight-hours per year and type of most flown airplane on this incidence rate.
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Methods
Study design
We performed a cohort study among commercial airline pilots. During a follow up 
period of 10 years, we assessed the occurrence of venous thrombotic events.
Participants: airline pilots
More than 95% of all commercial airline pilots in the Netherlands are  member 
of the Dutch Airline Pilot Association (APLA), in Dutch called the Vereniging 
Nederlandse Verkeersvliegers (VNV). All pilots who were a member of the VNV 
at some point during the follow-up period and who were still alive in March 
2003 were included in the study. Only the years that they were employed as a 
commercial airline pilot contributed to the total number of person years of follow 
up. The follow-up period started at January 1st 1993 or at start of employment 
as a commercial airline pilot if this was later. Follow-up ended at January 1st 
2003, when venous thrombosis was diagnosed or when the employment as a 
commercial airline pilot ended, whichever occurred first. The VNV provided us 
with names and addresses of all possible participants. For the main analysis, 
only individuals who were still members of the VNV at the time the study 
was conducted were included. However, airline pilots may have ended their 
membership of the VNV because of occurrence of disease, such as venous 
thrombosis. Therefore, we also sent questionnaires to all pilots who had ended 
their membership of the VNV during the follow up period. Furthermore, the VNV 
provided us with data (names, birth dates and last known addresses) on pilots 
that had been a member after January 1993, but who had deceased at the time 
we performed the study, which made it possible to assess whether any of the 
deceased pilots had died due to venous thrombosis. 
Control populations
The incidence rates of venous thrombosis in airline pilots were compared to two 
control populations. The first control group was the general Dutch population in 
1994. Age-specific incidence rates of venous thrombosis were obtained through 
Prismant, a Dutch institution that keeps statistics on incidence rates according to 
ICD-9 codes (Prismant, Utrecht, the Netherlands). 
 As a so-called healthy worker effect (individuals who are employed are 
generally more healthy than those who are not) is likely to be present when 
comparing to the general  population, we also included a second control group 
in our analysis. This control group consisted of a cohort of frequently flying 
employees of international companies and organisations. These employees had 
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been enrolled in a study on the absolute risk of venous thrombosis after air travel, 
the results of which have recently been published17. All employees in this cohort 
received electronic questionnaires on the occurrence of venous thrombosis 
during a 5-year follow up period. From this cohort of 8755 employees, those who 
had made at least 5 long haul flights per year on average were selected. Their 
incidence rate of venous thrombosis during the time they were not exposed to air 
travel was compared to that of the airline pilots.  
Questionnaires and flight data
All pilots were sent questionnaires with questions on general characteristics, 
such as age and sex, occurrence of venous thrombosis (at any time point 
during the follow up period), risk factors for venous thrombosis and flight data 
(number of flight hours per year, employing airline, types of airplanes flown and 
rank).  Questionnaires were sent through regular mail and non-responding pilots 
received up to 2 reminders with 2-week intervals.
Outcomes
Participants who reported venous thrombosis were asked to fill in a consent form 
for medical chart review. Only symptomatic first venous thrombotic events that 
were diagnosed with objective methods were considered. Deep vein thrombosis 
had to be diagnosed by compression ultrasonography or venography. Pulmonary 
embolism had to be diagnosed by spiral-CT scanning, high probability ventilation-
perfusion scanning or angiography. Superficial thrombophlebitis was not included. 
 Of the members who were deceased, we obtained causes of death from 
the central Bureau of Statistics (CBS), where all death certificates are registered. 
Statistical analysis
Incidence rates were calculated by dividing the number of events by the total 
number of person-years the pilots were followed. We calculated both the overall 
incidence rate as well as incidence rates per category based on age and number 
of flight-hours per year. In the control-populations, age-specific incidence 
rates were calculated in the same way. Standardized overall incidence rates in 
these populations were calculated as the weighted average of the age-specific 
incidence rates, using the age-distribution of the airline pilots as weights. The 
ratio of these incidence rates is the standardized morbidity ratio (SMR), which 
may also be seen as the ratio of the observed over the expected number of 
cases.  Standard errors were calculated based on a poisson distribution of the 
number of events. All statistical analyses were performed using SPSS version 
12.0 (SPSS, Chicago, Illinois, United States).
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Protection of privacy
Since the diagnosis of venous thrombosis may have a significant impact on the 
career of a commercial airline pilot (they are not allowed to fly while they use 
anticoagulant therapy), we assured extra protection of their personal data: all 
questionnaires were coded; the key that linked these codes to the names and 
addresses of the pilots was deposited at a notary public. Only one administrative 
employee, who was sworn to secrecy, had access to this key, and only in the 
presence of the notary public.
Results
A total of 3525 airline pilots had been a member of the VNV at some point 
between January 1st 1993 and January 1st 2003. Of these airline pilots, 3237 
were still a member of the VNV at the time they received the questionnaire 
(active members). A total of 288 pilots were no longer a member of the VNV 
when they received the questionnaire, but had been at some point during 
the follow up period (inactive members). Of the active members, 2474 pilots 
completed and returned the questionnaire, yielding a response of 76%. Of 
the 288 inactive members, 156 completed the questionnaire (response 54%). 
General characteristics of all participating active and in-active VNV-members 
are shown in Table 1.
Table 1: General characteristics of all participating airline pilots
Active members Archive members
Age, mean (range) 30.1 (18-63) 38.0 (19-60)
Sex, % male 96.1 97.3
Flight-hours/year, mean (range) 521  (0-1800) 516 (0-1500)
Rank
Captain (% of py) 46.5 59.6
First officer (% of py) 46.0 36.1
Second officer (% of py) 7.5 4.4
The total follow-up time of the participating pilots who were still a member of the 
VNV at the time the study was performed added up to 20 420 person-years, with 
a mean follow up time per pilot of 8.3 years (range 0-10 years).  
 Since there were only very few female pilots (n=100, 3.8%) none of whom 
had experienced venous thrombosis, we decided to restrict  all further analyses 
to male airline pilots only. The total follow up time of male airline pilots who were 
active members of the VNV when they received our questionnaire was 19 719 
person-years. 
The incidence of venous thrombosis in commercial airline pilots: a cohort study of 2630 pilots98
Venous thrombosis
During the total follow up time, 6 objectively confirmed events of deep vein 
thrombosis or pulmonary embolism occurred. All patients were men and active 
members of the VNV. Three pilots had developed a deep vein thrombosis of 
the leg, two suffered from both deep vein thrombosis of the leg and pulmonary 
embolism and one airline pilot was diagnosed with a deep vein thrombosis of the 
arm. None of the inactive members of the VNV reported occurrence of venous 
thrombosis. During the follow-up period, 54 pilots or ex-pilots died, but in none of 
these pilots venous thrombosis was reported as the primary cause of death.
Incidence rates and standardized morbidity ratios
The overall incidence rate of venous thrombosis in the cohort of active members 
of the VNV was 0.3/1000 person-years (CI95 0.1-0.6 per 1000 person-years). 
Age-specific incidence rates of the airline pilots and both control populations 
are shown in Table 2. Although the incidence rate was highest in the oldest age 
category, the occurrence of venous thrombosis did not clearly increase gradually 
with age.
Table 2:  Incidence rates in male airline pilots, the male general population and male frequently flying employees,  
stratified by age categories
Age PY Cases IR* pilots (CI95) IR population** IR employees# IR employees##
Overall 19 719 6 0.3 (0.1-0.6) 0.4 0.4 (0.2-1.8) 0.5
<20 41 0 0 (0-24.4) 0.1 0 0
20-25 1404 0 0 (0-0.7) 0.2 0 0
25-30 4025 1 0.2 (0-1.0) 0.2 0 0
30-35 4465 2 0.4 (0-1.3) 0.3 0 0.5 (0-2.1)
35-40 3486 0 0 (0-0.3) 0.4 0 0
40-45 2578 1 0.4 (0-1.6) 0.7 1.0 (0-4.2) 1.7 (0.4-3.8)
45-50 2006 0 0 (0-0.5) 0.9 1.0 (0-4.0) 0.4 (0-1.7)
50-55 1306 2 1.5 (0.1-4.5) 1.2 2.6 (0.7-7.7) 0.5 (0-2.2)
>55 408 0 0 (0-2.5) 0.4 0 3.3 (06-8.3)
Overall incidence rates in the general population and employees were standardized for the age of the airline pilots
*  IR: Incidence rate per 1000 person-years
**  IR population: incidence rate per 1000 person-years in the general male Dutch population
#   IR employees1: incidence rate per 1000 person-years in male employees who made at least 5 long haul flights during the follow up 
period of 5 years, while they were unexposed to air travel
##  IR employees1: incidence rate per 1000 person-years in all male employees, while they were unexposed to air travel
The age-standardized incidence rate in the general male Dutch population was 
0.4 per 1000 person-years. In employees who made at least 5 long haul flights 
in their follow up period of approximately 5 years, the standardized incidence 
rate of venous thrombosis while they were unexposed to air travel was also 
0.4/1000 person-years. When all employees were included, regardless of the 
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number of long haul flights made, the standardized incidence rate while they were 
unexposed to air travel was 0.5/1000 person-years.
The rate ratio (standardized morbidity ratio) comparing the airline pilots to the 
general Dutch population was 0.8 (CI95 0.7-1.0), i.e. the pilots experienced 
0.8 times the number of events that would have occurred in the cohort if the 
morbidity rates of the population had applied. The standardized morbidity ratio 
comparing the airline pilots to the employees who travelled at least 5 times during 
the follow up period was 0.7 (CI95 0.6-0.9), and it was 0.6 (CI95 0.5-0.7) when we 
compared airline pilots to all male employees that were included in that study.
Effect of number of flight hours per year and rank
Table 3 shows the incidence rate of venous thrombosis per category of flight-
hours per year. For the cases of venous thrombosis, the number of flight hours in 
the year preceding their thrombotic event was considered, since they probably 
flew less hours after their event in the year they developed venous thrombosis. 
There was no association between flight-hours per year and the incidence rate 
of venous thrombosis. In the same table, the effect of rank of the airline pilots 
is shown. The incidence rate of venous thrombosis was highest in second 
officers (0.7/1000 person-years, CI95 0-2.6/1000 person-years), but the numbers 
were too small to draw solid conclusions regarding the effect of rank on the 
occurrence of venous thrombosis.
Table 3: Incidence rates per number of flight-hours per year and for different ranks
Person-years Cases IR* (CI95)
Flight-hours per year
0-300 5856 1 0.2 (0-0.7)
300-600 6526 5 0.8 (0.2-1.6)
>600 3912 0 0 (0-0.3)
Rank
Captain 9462 3 0.3 (0.1-0.8)
First officer 9306 2 0.2 (0.01-0.6)
Second officer 15723 1 0.7 (0-2.6)
* IR: Incidence rate per 1000 person-years and corresponding 95% confidence intervals
Discussion 
In this follow up study among  2630 commercial airline pilots, with a total of 20 
420 person years of follow up time, the incidence rate of venous thrombosis 
was 0.3/1000 py (CI95 0.1-0.6). This incidence rate was slightly lower than in the 
general population and also than in a population of frequently flying employees 
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of international companies and organizations. Compared to the general Dutch 
population, the age-adjusted relative risk for venous thrombosis was 0.8 (CI95 
0.7-1.0). Compared to healthy employees, it was 0.7 (CI95 0.6-0.9). The incidence 
rate of venous thrombosis in the airline pilots did not increase with number of 
flight-hours per year, nor was it associated with the rank of the pilots. 
 The low incidence rate of venous thrombosis in commercial airline pilots 
may be explained by the fact that pilots in general are healthier than the general 
population: the so-called healthy worker effect  Several epidemiological studies 
have shown that overall mortality rates are lower in airline pilots than in the 
general population1-3. However, these epidemiological studies also showed that 
the incidence rate of cancer is increased in airline pilots. This may be caused by 
exposure to carcinogenic substances (jet fuel, cabin pollution, cosmic radiation). 
Despite exposure to these flight-related factors, or the higher prevalence of 
malignant diseases, no increased risk of venous thrombosis was found in this 
population. The healthy worker effect was countered by contrasting the pilots 
to another working population, but results were similar and not suggestive of an 
increased risk of thrombosis.
 A surprising finding in this study was that the incidence rate did not 
clearly increase with age. This may be due to chance, since the number of cases 
was small. However, in a previous study amongst frequently travelling employees, 
the incidence rate of venous thrombosis was highest in the lowest age-category 
as well17. In the previous study, this was partly explained by a phenomenon 
called ‘attrition of susceptibles’, meaning that susceptible individuals are likely to 
develop a disease shortly after start of exposure to a risk factor. This may also be 
the case here, that airline pilots who develop venous thrombosis because of their 
profession are likely to develop thrombosis shortly after start of exposure (their 
employment), and subsequently seek different employment.
 We may have underestimated the risk of venous thrombosis in airline 
pilots, because they may have been reluctant to confirm they suffered from 
venous thrombosis in the questionnaire, due to fear for possible consequences, 
i.e. losing their job. We tried to avoid non-respondence or misclassification by 
ensuring and communicating complete protection of privacy in our study.  Our 
finding that the incidence rate of venous thrombosis in pilots is lower than in 
the general population is supported by the absence of any airline pilots who 
died of pulmonary embolism during the follow up period. If the risk of venous 
thrombosis amongst Dutch airline pilots would have been substantially higher 
than in the general Dutch population, one would also have expected fatal cases. 
Another finding that supports our conclusion that the risk of venous thrombosis 
is not increased in airline pilots is that we did not find an association between the 
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number of flight hours per year and the risk of venous thrombosis, i.e. no ‘dose-
response relation’.
 From this cohort study amongst Dutch airline pilots, we conclude that the 
risk of venous thrombosis is not increased in commercial airline pilots. 
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In venous thrombosis (VT), a blood clot develops in a vein, usually a deep vein 
of the leg, causing obstruction of the blood flow. This results in swelling, redness 
and pain of the affected limb. When part of this blood clot detaches, a potentially 
fatal condition, called pulmonary embolism (PE), may occur. A frequent 
complication of venous thrombosis is the post-thrombotic syndrome, a disabling 
condition with persistent swelling and pain of the affected extremity. 
Individuals at older age and those with certain genetic risk factors, such as 
the factor V Leiden mutation, the prothrombin 20210A mutation, protein S or C 
deficiency and Antithrombin III deficiency, are at increased risk for developing 
venous thrombosis. However, this usually does not occur until environmental 
risk factors are present as well. Common environmental factors that are known 
to increase the risk of venous thrombosis are surgery (especially orthopedic 
surgery), trauma, immobilization, plaster cast, malignant diseases, pregnancy 
or delivery and use of oral contraceptive- or hormone replacement therapy. 
Another environmental risk factor that may increase the risk of venous 
thrombosis is long distance travel.
Long distance travel may lead to blood clot formation due to several 
pathophysiological mechanisms. Around 1850, the pathologist Virchow already 
posed three possible causes of thrombosis: venous stasis, damage of the vessel 
wall and changes in blood composition. Damage of the vessel wall seems to be 
more important in the development of arterial thrombosis (such as a myocardial 
infarction or ischemic stroke). In air travel, both venous stasis and changes in 
the blood composition may occur. Firstly, venous stasis may be the result of the 
prolonged immobility that occurs when passengers sit in a cramped position in 
an airplane seat. Dehydration due to the low air humidity in an airplane may lead 
to venous stasis as well. Furthermore, changes in the blood composition may 
arise due to the hypobaric hypoxia present in airplane cabins, exposure to jet fuel 
or other flight-related factors.
This thesis describes the results of several studies on epidemiological aspects of 
the association between long distance travel and venous thrombosis.
The first chapter serves as an introduction and provides an outline of the studies 
in this thesis. 
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Chapter 2 is a review that summarizes all literature available on the association 
between travel and venous thrombosis up to January 1st 2007. Both 
epidemiological research and studies on possible mechanisms responsible for 
venous thrombosis during and after travel are discussed. From this review article, 
we conclude that long distance travel increases the risk of venous thrombosis 
approximately 2-4 fold. Furthermore, a dose-response relationship between the 
risk of severe pulmonary embolism and duration of travel strongly suggests a 
causal association. The mechanism responsible for this increased risk of VT 
after air travel was not sufficiently studied to draw solid conclusions, but one 
controlled study showed evidence that not only immobilization but other air travel 
specific factors lead to coagulation activation. 
In the 3rd chapter the use of prophylactic measures to prevent travel-related 
thrombosis by visitors of three international conferences in Australia was 
assessed through a survey that was sent to all overseas attendants of these 
conferences. We showed that a considerable number (over 80%) of them used 
some kind of preventive measure during travel. The type of preventive measures 
varied between conference, professional background, risk groups and nationality. 
Delegates of a haemostasis and thrombosis conference and especially medical 
doctors used more aggressive prophylaxis than delegates of the conferences 
that did not concern thrombosis.
The 4th chapter describes a study in a cohort of frequently flying employees of 
large international companies or organizations. In this cohort, the absolute risk 
of developing symptomatic venous thrombosis within 8 weeks of flights longer 
than 4 hours was 1 in 4656 flights. This risk increased with flight duration, up 
to 1 in 1264 after flights longer than 16 hours. Furthermore, the risk increased 
when employees were exposed to several flights in a short period of time (since 
exposure to air travel was defined as a period of 8 weeks after a flight, these 8-
week time-windows were frequently overlapping) and it decreased with time after 
a long haul flight. The risk returned to baseline after approximately 8 weeks after 
the flight. Individuals that were most at risk for developing travel-related venous 
thrombosis in this cohort were young travellers, women – especially those taking 
oral contraceptives – , individuals who were particularly short or tall and those 
with a body mass index over 25kg/m2.
In the 5th chapter, the effect of increased coagulation factors and that of 
interaction with other risk factors for venous thrombosis in long distance travellers 
is assessed. In a case-control study amongst 334 long distance travellers, we 
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demonstrated an increased risk of venous thrombosis in individuals with high 
levels of coagulation factors II and VIII. The relative risk increased with the 
number of coagulation abnormalities (factor II, VIII and IX, prothrombin mutation 
and factor V Leiden mutation) and with the overall number of risk factors present 
per individual (coagulation factors, high body mass index and oral contraceptive 
use). The relative risk was highest in female travellers using oral contraceptives 
who also had high levels of FVIII (odds ratio 51.7, CI95 5.4-498). Combinations 
with the factor V Leiden mutation were associated with a particularly high relative 
risk as well. All these effects were superimposed on the relative risk of travel itself, 
which is about two in this population.
In the 6th chapter, the effect of other transient risk factors for venous 
thrombosis on the risk of air-travel related venous thrombosis was evaluated. 
Transient risk factors that had the most pronounced effect on the risk of 
travel-related venous thrombosis were recent surgery, oral contraceptive use 
and malignant diseases.
The 7th chapter describes the results of a study on occurrence of venous 
thrombosis amongst commercial airline pilots in the Netherlands. In this follow 
up study amongst 2630 pilots, the incidence rate of venous thrombosis was 
0.3/1000 person years (CI95 0.1-0.6). This incidence rate was lower than in the 
general Dutch population and in a population of frequently flying employees 
of international companies or organisations. Compared to the general Dutch 
population, the age- and sex adjusted relative risk for venous thrombosis was 
0.8 (CI95 0.7-1.0). The incidence rate of venous thrombosis in the airline pilots 
did not increase with number of flight-hours per year, nor was it associated with 
rank of the pilots. 
From all studies described in this thesis, we conclude that the absolute risk 
of venous thrombosis after long distance travel in the general population 
is not high enough to promote widespread use of aggressive prophylaxis, 
such as anticoagulant therapy. The general advice that is now provided to 
air travellers (prevention of venous stasis by walking around, refraining from 
sleeping medication and drinking plenty non-alcoholic beverages) seems 
sufficient for most healthy air travellers although the effect of these measures 
has insufficiently been established. However, some subgroups of travellers are 
at increased risk for developing travel-related venous thrombosis, especially 
when several risk factors are combined in one traveller. For these subgroups 
of people with a highly increased risk, the risk-benefit ratio may favour the use 
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of prophylactic measures. To date, it is not known which prophylactic measure 
is most suitable for prevention of travel-related thrombosis. Large randomized 
trials are required to assess who would benefit most from special exercises, 
elastic compression stockings, mechanical devices that promote venous blood 







Veneuze trombose is een aandoening waarbij zich een bloedstolsel vormt op de 
verkeerde plaats, meestal in een van de venen van het been. Hierdoor wordt de 
terugvloed van het bloed richting het hart belemmerd, resulterend in zwelling, 
roodheid en pijn van het aangedane been. Wanneer een deel van een dergelijk 
bloedstolsel los raakt, kan dit door de bloedstroom naar de longen worden ge-
transporteerd, waar het een levensgevaarlijke longembolie kan veroorzaken. 
Een frequent voorkomende, potentieel invaliderende complicatie van veneuze 
trombose is het zogenaamde post-trombotische syndroom, waarbij de zwelling 
en pijn van het aangedane been persisteert.
Ouderen en mensen met bepaalde genetische risicofactoren, zoals de factor 
V Leiden mutatie, de protëine 20210A mutatie, protëine S of C deficiëntie en 
Antithrombine deficiëntie hebben een verhoogd risico op het ontwikkelen van 
veneuze trombose. Een trombus ontwikkelt zich echter pas wanneer er ev-
eneens bepaalde omgevingsfactoren aanwezig zijn die het risico extra verhogen. 
Bekende verworven risicofactoren zijn recente chirurgie (met name orthopae-
dische chirurgie), trauma, immobilisatie, gips, maligniteiten, zwangerschap, de 
kraamperiode en het gebruik van orale anticonceptie of hormoonvervangende 
therapie. Een andere omgevingsfactor die het risico op veneuze trombose ver-
hoogt is reizen per vliegtuig. 
Langdurig vliegen kan tot de vorming van bloedstolsels leiden op verschil-
lende manieren. Rond 1850 postuleerde de patholoog Virchow drie factoren die 
pathofysiologisch een rol spelen bij het ontstaan van een thrombus: veneuze 
stase, beschadiging van de vaatwand en een veranderde samenstelling van 
het bloed. Beschadiging van de vaatwand lijkt een grotere rol te spelen bij het 
ontstaan van arteriele trombose (zoals een myocardinfarct of ischaemisch CVA). 
Reizen per vliegtuig zou zowel veneuze stase als een veranderende samenstel-
ling van het bloed kunnen veroorzaken. Veneuze stase kan het gevolg zijn van 
langdurig stilzitten in de beperkte ruimte van een vliegtuigstoel. Uitdroging, ten 
gevolge van de verminderde luchtvochtigheid in een vliegtuig, zou eveneens tot 
veneuze stase kunnen leiden. Een veranderende samenstelling van het bloed zou 
een gevolg kunnen zijn van de hypobare hypoxie, brandstoffen of andere vliegtu-
ig-gerelateerde factoren waaraan een vliegtuig passagier is blootgesteld.
Dit proefschrift beschrijft een aantal onderzoekingen naar epidemiologische as-
pecten van de relatie tussen reizen per vliegtuig en veneuze trombose.
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Het eerste hoofdstuk dient als een inleiding, waarin het doel van de studies die 
zijn beschreven in dit proefschrift wordt uitgelegd.
Hoofdstuk 2 bestaat uit een overzichtsartikel, waarin alle reeds beschikbare liter-
atuur op het gebied van veneuze trombose en reizen per vliegtuig op een system-
atische manier wordt samengevat. Zowel epidemiologische als meer pathofysi-
ologische studies, waarin het mechanisme verantwoordelijk voor het verhoogde 
risico op veneuze trombose na vliegen wordt onderzocht, worden in dit hoofd-
stuk bediscussieerd. Uit dit artikel kon worden geconcludeerd dat het risico op 
veneuze trombose na een lange vlucht ongeveer 2-4 keer verhoogd is. Bovendien 
bestaat er een zogenaamde dosis-respons relatie tussen het risico op ernstige 
longembolieën en de duur van de vliegreis, hetgeen sterk pleit voor een causale 
relatie tussen vliegen en trombose. Het mechanisme verantwoordelijk voor dit 
verhoogde risico op veneuze trombose na vliegen werd nog niet voldoende be-
studeerd voor het trekken van eenduidige conclusies, maar een gecontroleerde 
studie liet bewijs zien dat niet alleen immobilisatie, maar ook vliegtuig-specifieke 
factoren, zoals de lagere luchtdruk of het lagere zuurstofgehalte in een vliegtuig 
verantwoordelijk zouden kunnen zijn voor stollingsactivatie.
In het derde hoofdstuk wordt gekeken naar het gebruik van voorzorgsmaatrege-
len om vliegreis-gerelateerde veneuze trombose te voorkomen onder bezoekers 
van 3 grote internationale conferenties die gehouden werden in Australië. Dit 
werd gedaan door middel van een vragenlijst onderzoek onder deze bezoekers. 
In dit hoofdstuk lieten wij zien dat een groot deel (80%) van de bezoekers een of 
meerdere voorzorgsmaatregelen had genomen. Het soort preventieve maatregel 
wisselde sterk per conferentie, professionele achtergrond, risicoprofiel en na-
tionaliteit van de bezoeker. Bezoekers van een congres over trombose en hae-
mostase, vooral de artsen onder hen, gebruikten meer agressieve profylactische 
maatregelen dan deelnemers aan de congressen die niet over trombose gingen.
In het vierde hoofdstuk wordt een onderzoek beschreven dat werd gedaan in een 
cohort van frequent vliegende werknemers van grote internationale bedrijven en 
organisaties. In dit cohort was het absolute risico op het krijgen van een symp-
tomatische veneuze trombose in de eerste 8 weken na een vlucht van minimaal 
4 uur 1 op de 4656 vluchten. Dit risico nam toe met de duur van de vlucht, naar 1 
op de 1264 vluchten na vluchten langer dan 16 uur. Bovendien was het risico ho-
ger wanneer werknemers in korte tijd aan meerdere vluchten werden blootgesteld 
en nam het risico af met de duur na een vlucht. Het risico werd kleiner naarmate 
een vlucht langer geleden was en na ongeveer 8 weken was het risico op ve-
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neuze trombose niet langer verhoogd. In dit cohort hadden jongere mensen, 
vrouwen – vooral wanneer zij ook orale anticonceptie gebruikten – buitengewoon 
lange of korte werknemers en diegenen met een body mass index hoger dan 25 
kg/m2 een groter risico.
In hoofdstuk 5 wordt gekeken naar het effect van voorbijgaande risicofactoren 
voor veneuze trombose op het risico van reis-gerelateerde trombose, in hetzelfde 
cohort dat werd beschreven in hoofdstuk 4. Voorbijgaande risicofactoren die het 
risico op veneuze trombose het meest verhoogden waren recente operaties, het 
gebruik van orale anticonceptie en maligne aandoeningen. 
In hoofdstuk 6 wordt het effect van verhoogde waarden of activiteit van 
stollingsfactoren en hun interactie met andere risicofactoren voor veneuze 
trombose onder reizigers beschreven. In een groot case-controle onderzoek 
onder 334 lange-afstands reizigers lieten wij een verhoogd risico op veneuze 
trombose zien onder personen met verhoogde waarden van de stollingsfactoren 
II en VIII. Bovendien nam het risico toe met het aantal procoagulante afwijkingen 
(verhoogde spiegels van de factoren II en VIII en/of de aanwezigheid van de 
factor V Leiden mutatie of de prothrombine 20210A mutatie) en met het totaal 
aantal aanwezige risicofactoren (de bovengenoemde procoagulante factoren, 
een hoge body mass index, gebruik van orale anticonceptie en het hebben 
van een positieve familieanamnese voor veneuze trombose). Het risico in dit 
onderzoek was het hoogst onder vrouwelijke reizigers die orale anticonceptie 
gebruikten en eveneens een verhoogde factor VIII waarde hadden. Combinaties 
met de factor V Leiden mutatie leidden eveneens tot een sterk verhoogd risico. Al 
deze effecten kwam bovenop het relatieve risico van reizen zelf, wat ongeveer 2 
was in deze populatie. 
In het zevende hoofdstuk worden de resultaten van een onderzoek onder 
Nederlandse verkeersvliegers gepresenteerd. In dit vervolgonderzoek 
onder 2630 piloten was het incidentiecijfer voor veneuze trombose 0.3 per 
1000 persoonsjaren. Dit incidentiecijfer bleek lager dan dat in de algemene 
Nederlandse bevolking en dat in een cohort van frequent vliegende werknemers 
van internationale bedrijven en organisaties (beschreven in hoofdstuk 4 van dit 
proefschrift). Vergeleken bij de Nederlandse bevolking was het voor leeftijd en 
geslacht gecorrigeerde relatieve risico 0.8 (95% betrouwbaarheids interval 0.7-
1.0). Het incidentiecijfer voor veneuze trombose onder deze verkeersvliegers nam 
niet toe met het aantal vluchten per jaar of de rang van de piloten. 
Uit alle in dit proefschrift beschreven onderzoeken concluderen wij dat het 
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absolute risico op het ontwikkelen van veneuze trombose na een lange vliegreis 
in de algemene bevolking niet hoog genoeg is voor het ondersteunen van 
veelvuldig gebruik van potentieel gevaarlijke voorzorgsmaatregelen, zoals 
het gebruik van antistolling. Het algemene advies dat tot nu toe aan reizigers 
gegeven wordt (voorkomen van veneuze stase door genoeg te bewegen en veel 
niet-alcoholische dranken te gebruiken) lijkt afdoende voor de meeste gezonde 
vliegtuigpassagiers, ook al is het effect van deze maatregelen niet aangetoond. 
Er zijn echter subgroepen van reizigers die een verhoogd risico op veneuze 
trombose hebben, vooral wanneer er meerdere risico factoren voor trombose 
tegelijk aanwezig zijn. In deze groepen reizigers zou het voordeel van dergelijke 
voorzorgsmaatregelen wel op kunnen wegen tegen het risico ervan. Tot op heden 
is het echter niet bekend welke reizigers het meeste baat zouden kunnen hebben 
bij welke voorzorgsmaatregel. Grote gerandomiseerde onderzoeken onder hoog-
risico reizigers zijn dan ook essentieel om te kunnen stellen welke reizigers in 
aanmerking komen voor het gebruik van bijvoorbeeld elastische steunkousen, 
speciale apparaatjes die de doorbloeding van de benen bevorderen of zelfs 




Promoveren is veel meer dan het schrijven van een proefschrift. De jaren van mijn 
promotie-onderzoek heb ik ervaren als een bijzonder boeiende, soms moeilijke, 
maar meestal erg leuke en vooral leerzame periode, waarin ik werd bijgestaan 
door een groot aantal mensen zonder wie mijn promotieonderzoek een stuk 
minder aangenaam en succesvol was geweest.
First of all, I would like to thank all companies and organisations that participated 
in the WRIGHT Professional Travellers study: Luc Robyn, Bart Terlunen, Hans Berg 
and Carl Bollin, Paul Boelens, Lennart Dimberg, Jasminka Goldoni, Craig Hooper, 
Sidney Stein and Timothy Crimmins. Because of your kind help, we were able to 
include almost 10.000 employees in our study. Thank you very much for all your 
efforts. 
De piloten-studie was niet mogelijk geweest zonder steun van de Vereniging 
Nederlandse Verkeersvliegers. Veel dank dat ik gebruik heb mogen maken van 
jullie gegevens om zo te kunnen onderzoeken hoe vaak (of eigenlijk hoe weinig) 
veneuze trombose bij Nederlandse piloten voorkomt. Lucie Timmers, bedankt dat 
jij hebt willen fungeren als door de notaris beëdigd ‘sleutelfiguur’.
Ook wil ik graag alle medewerkers van het MEGA-team en met name Carine 
Doggen bedanken. In de MEGA studie heb ik kunnen onderzoeken wat het effect 
is van verhoogde waarden van stollingsfactoren op het risico op reis-gerelateerde 
trombose. Heel veel dank dat ik van jullie data gebruik heb mogen maken!
Uiteraard wil ik ook alle collega’s van de epidemiologie bedanken. Tijdens 
mijn 4 jaar op de afdeling heb ik enorm veel kunnen leren op het gebied van 
epidemiologie (4 jaar methodenuur!), dat was zonder jullie niet mogelijk geweest. 
Met name Renée, Irene en Sverre, veel dank voor alle gezelligheid, jullie 
luisterend oor, de vele kopjes thee en stukken chocolade en uiteraard de vele 
leerzame momenten. Marieke, eerst prettige collega, nu goede vriendin, wat ben 
ik blij dat ik jou tijdens onze gezamenlijke epi-jaren heb leren kennen! 
Ook alle stollingscollega’s (zowel in het AMC als in het LUMC) wil ik graag bedanken 
voor de plezierige samenwerking. De stollingdiensten vormden een welkome 
afwisseling tijdens mijn onderzoeksperiode. Ik vond het erg inspirerend om naast het 
onderzoek klinische ervaring op te doen op het gebied van (anti)stolling. Jeroen en 
Felix, Saskia, Erik en Victor, heel veel dank voor jullie altijd geduldige supervisie en 
uitleg.  
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Eva, Yf en Anja, onze gezamenlijke cursusreis naar Sicilië, helemaal aan het 
begin van ons promotietraject, was het begin van Factor IV Leiden en een hechte 
vriendschap waar ik tot op de dag van vandaag enorm blij mee ben. Veel dank 
voor al jullie steun en de mooie momenten die we samen hebben meegemaakt. 
Yf, na de vele reisjes die we hebben gemaakt ben ik erg blij dat je ook straks als 
paranimf naast me zult staan. Eef, jouw bijna ‘moederlijke’ bezorgdheid over Yf 
en mij heeft me altijd een erg goed gevoel gegeven, wat fijn dat we nu bijna bij 
elkaar om de hoek wonen! Anja, samen zijn we vol enthousiasme aan dit enorme 
project begonnen en ik vind het geweldig dat we het nu ook samen af kunnen 
ronden. We gaan er een onvergetelijke dag van maken!
Ook buiten het LUMC waren er een aantal mensen die me enorm hebben 
geholpen. 
Allereerst Olga, wat fijn dat jij de layout en omslag van mijn proefschrift wilde 
maken, ik ben erg blij met het resultaat. Lieve Alette, farel-meisjes en alle andere 
vrienden, nooit meer promotiestress! Veel dank voor al jullie steun en jullie geduld 
als ik weer eens afhaakte of gestresst was als gevolg van mijn onderzoek. 
Chris, lieve grote broer. Ondanks dat je het zelf niet altijd makkelijk had de 
afgelopen jaren had je altijd een luisterend oor voor je kleine zusje en was je altijd 
bereid mijn schrijfsels te lezen als ik je daarom vroeg. Wat fijn dat je me straks 
ook als paranimf wilt bijstaan.
Lieve mam en pap, dankzij jullie ben ik wie ik ben. Het geeft een ontzettend goed 
gevoel om altijd op jullie onvoorwaardelijke steun en liefde te kunnen rekenen. 
Zonder jullie had ik het nooit gered.
Liefste Tamar. Door jouw komst in mijn leven waren de laatste loodjes van mijn 
promotie-traject stukken minder zwaar. Jij maakt me elke dag intens gelukkig en 
ik heb dan ook enorm veel zin in alle leuke en spannende dingen die we in de 
toekomst samen zullen doen.
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